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A B S T R A C T
Background
The definition of sepsis has evolved over time, along with the clinical and scientific knowledge behind it. For years, sepsis was defined
as a systemic inflammatory response syndrome (SIRS) in the presence of a documented or suspected infection. At present, sepsis is
defined as a life-threatening organ dysfunction resulting from a dysregulated host response to infection. Even though sepsis is one of the
leading causes of mortality in critically ill patients, and the World Health Organization (WHO) recognizes it as a healthcare priority,
it still lacks an accurate diagnostic test. Determining the accuracy of interleukin-6 (IL-6) concentrations in plasma, which is proposed
as a new biomarker for the diagnosis of sepsis, might be helpful to provide adequate and timely management of critically ill patients,
and thus reduce the morbidity and mortality associated with this condition.
Objectives
To determine the diagnostic accuracy of plasma interleukin-6 (IL-6) concentration for the diagnosis of bacterial sepsis in critically ill
adults.
Search methods
We searched CENTRAL, MEDLINE, Embase, LILACS, and Web of Science on 25 January 2019. We screened references in the
included studies to identify additional studies. We did not apply any language restriction to the electronic searches.
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Selection criteria
We included diagnostic accuracy studies enrolling critically ill adults aged 18 years or older under suspicion of sepsis during their
hospitalization, where IL-6 concentrations were evaluated by serological measurement.
Data collection and analysis
Two review authors independently screened the references to identify relevant studies and extracted data.We assessed themethodological
quality of studies using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. We estimated a summary receiver
operating characteristic (SROC) curve by fitting a hierarchical summary ROC (HSROC) non-linear mixed model. We explored sources
of heterogeneity using theHSROCmodel parameters. We conducted all analyses in the SAS statistical software package and R software.
Main results
We included 23 studies (n = 4192) assessing the accuracy of IL-6 for the diagnosis of sepsis in critically ill adults. Twenty studies that
were available as conference proceedings only are awaiting classification. The included participants were heterogeneous in terms of
their distribution of age, gender, main diagnosis, setting, country, positivity threshold, sepsis criteria, year of publication, and origin of
infection, among other factors. Prevalence of sepsis greatly varied across studies, ranging from 12% to 78%. We considered all studies
to be at high risk of bias due to issues related to the index test domain in QUADAS-2. The SROC curve showed a great dispersion in
individual studies accuracy estimates (21 studies, 3650 adult patients), therefore the considerable heterogeneity in the collected data
prevented us from calculating formal accuracy estimates. Using a fixed prevalence of sepsis of 50% and a fixed specificity of 74%, we
found a sensitivity of 66% (95% confidence interval 60 to 72). If we test a cohort 1000 adult patients under suspicion of sepsis with
IL-6, we will find that 330 patients would receive appropriate and timely antibiotic therapy, while 130 patients would be wrongly
considered to have sepsis. In addition, 370 out of 1000 patients would avoid unnecessary antibiotic therapy, and 170 patients would
have been undiagnosed of sepsis. This numerical approach should be interpreted with caution due to the limitations described above.
Authors’ conclusions
Our evidence assessment of plasma interleukin-6 concentrations for the diagnosis of sepsis in critically ill adults reveals several limitations.
High heterogeneity of collected evidence regarding the main diagnosis, setting, country, positivity threshold, sepsis criteria, year of
publication, and the origin of infection, among other factors, along with the potential number of misclassifications, remain significant
constraints for its implementation. The 20 conference proceedings assessed as studies awaiting classification may alter the conclusions
of the review once they are fully published and evaluated. Further studies about the accuracy of interleukin-6 for the diagnosis of sepsis
in adults that apply rigorous methodology for conducting diagnostic test accuracy studies are needed. The conclusions of the review
will likely change once the 20 studies pending publication are fully published and included.
P L A I N L A N G U A G E S U M M A R Y
Levels of interleukin-6 in identifying severely ill adult patients with sepsis
Review question
We evaluated the evidence on the ability of interleukin-6 (IL-6) levels in plasma to identify adult patients with sepsis. Interleukin-6 is
a cytokine (a broad and loose category of small proteins) secreted by immune cells that mediates a wide range of biological activities.
Background
Sepsis is a potentially life-threatening response by the immune system to an infection that can result in tissue damage, organ failure, and
even death, and should be considered as a medical emergency. About 288 septic cases by 100,000 person-years occur in hospital settings,
and 17% of those patients could die. Early identification of patients having sepsis is the first step for immediate medical management,
which is essential to avoid further complications and death. Treatment consists mainly of the use of antibiotics (a drug that inhibits
the growth of dangerous micro-organisms). Several tools have been proposed for sepsis diagnosis, as well as the physical examination
of blood cultures (the assessment of blood samples to identify micro-organisms causing the infection). Interleukin-6 is a molecule that
helps in the communication of cells during the body’s response to an infection. It has been suggested that the measurement of levels
of IL-6 in the plasma from blood samples during the onset of sepsis can be helpful in identifying sepsis patients early and initiating
adequate treatment.
Study characteristics
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We performed a thorough literature search for studies reporting the use of IL-6 levels for detection of sepsis up to January 2019. We
found 23 studies enrolling 4192 severely ill adults.
Key results
Our assessment of the evidence reveals the complexity of the research topic, represented in the high variability of information reported
by the studies. We found the characteristics of assessed patients to vary considerably between studies in terms of age, gender, setting,
initial diagnosis, indicative value for sepsis, and source of infection, among other factors. This variability in the collected data prevented
a formal numerical synthesis of the findings. Using the available data to perform an approximated estimation of the consequences, we
found that 700 out of 1000 patients under suspicion of sepsis might be correctly classified, but 130 out of 1000 patients would be
wrongly considered as having sepsis, while 170 out of 1000 patients might be incorrectly considered as not having sepsis. These errors
would result in a serious increase in the risk of further morbidity and death due to delays of adequate treatment. This information
should be interpreted with caution due to limitations in the collected data.
Quality of the evidence
We judged the included studies to have important limitations in their validity, hence they are at high risk of providing distorted results
(i.e. to be at high risk of bias).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Population Crit ically ill adults under suspicion of sepsis (i.e. with SIRS symptoms)
Prior testing Physical examinat ion and history
Index test Plasma interleukin-6, measured before ant ibiot ic treatment. Cut-of f for posit ivity ranged f rom 40 to 200,000 pg/ mL
Role of the test Triage: First test for pat ients with SIRS symptoms and wait ing for further results (i.e. culture)
Setting Intensive care units, emergency departments, inst itut ional sett ing (no details provided)
Reference stan-
dard
3 sepsis def init ions derived f rom expert consensus were considered valid reference standards:
• 1991 ACCP/ SCCM Consensus Conference (Bone 1992);
• 2001 SCCM/ ESICM/ ACCP/ ATS/ SIS consensus (Levy 2003);
• 2015 ESICM/ SCCM consensus (Singer 2016).
Sepsis criteria were applied by crit ical care, emergency, or internal medicine clinicians
Index test Prevalence Number of stud-
ies
Number of partic-
ipants
Sensitivity (under
fixed specificity)
1
Specificity
(fixed)2
Number of false
positives out of
1000 patients
Number of false
negatives out of
1000 patients
Comments
Plasma
interleukin-6 con-
centrat ion
12% 21 3650 66% (95% conf i-
dence interval 60
to 72)
74% 229 41 High heterogene-
ity of collected
evidence remains
a signif icant con-
straint for plasma
interleukin-6 im-
plementat ion
50% 130 170
78% 57 265
1HSROC (hierarchical summary receiver operat ing characterist ic) parameters were used to illustrate sensit ivity for a f ixed
specif icity.
2Median specif icity est imated f rom included studies.
Abbreviations: AB: ant ibiot ic;ACCP: American College of Chest Physicians;ATS: American Thoracic Society;ESICM : European
Society of Intensive Care Medicine; QUADAS: Quality Assessment of Diagnost ic Accuracy Studies; SCCM : Society of Crit ical
Care Medicine; SIRS: systemic inf lammatory response syndrome; SIS: Surgical Infect ion Society.
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B A C K G R O U N D
The diagnosis of sepsis in critically ill patients with non-specific
findings of an acute inflammatory process can be challenging
(Harbarth 2001). In a significant number of cases, the diagnosis
of sepsis becomes clear after completing the patient medical his-
tory and physical examination. However, in other circumstances,
including comatose, elderly, or pregnant patients, the diagnosis of
sepsis remains difficult (Abraham 2000). Currently, the diagno-
sis of sepsis is based on clinical findings and the presence of or-
gan dysfunction (Singer 2016). Several new biological indicators
(biomarkers) have been proposed for the diagnosis of sepsis, but
no single one of them has gained unanimous acceptance (Rello
2017; van Engelen 2018).
Target condition being diagnosed
The clinical understanding of sepsis has evolved over the years.
For several years, sepsis was defined as a systemic inflammatory
response syndrome (SIRS) in the presence of a documented or
suspected infection (Dellinger 2013; Levy 2003; Shankar-Hari
2015). In 2001, the Society of Critical Care Medicine (SCCM),
the European Society of Intensive Care Medicine (ESICM), the
American College of Chest Physicians (ACCP), the American
Thoracic Society (ATS), and the Surgical Infection Society (SIS)
stated that SIRS involves changes, by unknown causes, of clinical
baseline parameters such as body temperature, hypothermia, heart
rate, respiratory rate, and white blood cell count, among others
(Levy 2003; Rangel-Frausto 1995). Under these criteria, in pa-
tients with symptoms of sepsis, the attending physician used the
term ’clinically suspected infection’ to indicate the suspicion of
an ongoing infection, followed by the prescription of immediate
initiation of antimicrobial therapy and submission of a request for
a complete set of tests to determine the presence or absence of an
infection (Rangel-Frausto 1995).
In 2015, a consensus task force of the ESICM and the SCCM up-
dated the definition of sepsis and septic shock, which is currently in
use (Singer 2016). At present, sepsis is defined as a life-threatening
organ dysfunction resulting from a dysregulated host response to
infection (Singer 2016). The new definition withdraws the terms
’SIRS’ and ’severe sepsis’ and instead prioritizes organ dysfunc-
tion. Organ dysfunction can be identified as an acute change in
the total Sequential Organ Failure Assessment (SOFA) score ≥
2 points due to infection. A SOFA score ≥ 2 reflects an overall
mortality risk of approximately 10% in a general hospital popu-
lation with suspected infection (Singer 2016). In addition, septic
shock is defined as a subset of sepsis in which underlying circu-
latory and cellular/metabolic abnormalities are profound enough
to increase mortality (Singer 2016). Patients with septic shock can
be identified from a clinical construct of sepsis with persisting hy-
potension requiring vasopressors to maintain blood pressure and
hyperlactataemia despite adequate volume resuscitation. Hospital
mortality in patients with septic shock has been estimated to be
higher than 40% (Singer 2016).
The worldwide burden of sepsis is difficult to estimate due to the
variability of settings, designs, and sepsis criteria found in the vari-
ous studies (Fleischmann 2016). Based on information from high-
income countries only, Fleischmann and colleagues estimated a
population incidence rate of 288 hospital-treated sepsis cases per
100,000 person-years, with an increase to 437 cases per 100,000
person-years in the last 13 years. In addition, an extrapolation of
information from the last decade suggests that a total annual num-
ber of 31.5 million sepsis and 19.4 million severe sepsis cases are
treated worldwide each year, with a case fatality rate of 5.3 million
deaths (Fleischmann 2016). A retrospective cohort study in seven
states in the USA identified 192,980 cases of severe sepsis, with
an estimated incidence of sepsis of 3 cases per 1000 persons at
the population level, and 2.26 cases per 100 hospital discharges;
the authors projected an increase in severe sepsis of 1.5% per year
(Angus 2001). Finfer 2004 reported that 11.8 per 100 patients
admitted to an intensive care unit (ICU) between 1999 and 2000
were diagnosed with severe sepsis, with an incidence of 0.77 (95%
confidence interval (CI) 0.76 to 0.79) per 1000 adult patients.
According to Kumar 2011, the mortality rate for severe sepsis de-
creased from 39% to 27% between 2000 and 2007. However, the
rates of mortality were higher in people with more organ systems
failing. In 2011, the average cost for the treatment of severe sep-
sis was USD 22,100 per case, with potentially higher expenses
depending on patient age, the need for surgical procedures, the
presence of organ failure, and variation in costs charged by ICUs
(Angus 2001).
Sepsis originates as an infection caused by bacteria, fungus, virus,
or parasites (Dellinger 2013). One half (52%) of sepsis cases in
hospitals in the USA originate from gram-positive bacteria (Finfer
2004). For bacteria to cause infections, they must evade the im-
mune system of the host, either at the site of infection or in
the bloodstream. Innate immune cells recognize pathogenic mi-
cro-organisms by sensing common microbial structures known as
pathogen-associated molecular patterns, such as lipoteichoic acid,
lipopeptides, lipopolysaccharides, and nucleic acids (Christaki
2014). The first barriers against pathogen invasion are the skin and
mucosal surfaces. Neutrophils are the primary andmost important
cells that defend the host against invading pathogens.Othermech-
anisms of defence include monocytes and macrophages, cytokines
storm, and complement activation. The pathogenesis presents
unique features, as they are under the influence of the genetic
makeup of the host. (Christaki 2014).
A deficient immune system is a risk factor for the development of
sepsis, which can be caused by functional asplenia, an infectious
disease, or haematologic malignancy (Dellinger 2013). Moreover,
malignancy has been associatedwith an increase in the incidence of
sepsis, with a risk ratio of 9.77 (95%CI 9.67 to 9.88) as compared
to non-cancer patients (Danai 2006). Complications associated
with the onset of sepsis include acute renal failure, polyneuropa-
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thy, cardiomyopathy, and multiple organ dysfunction (Latronico
2011; Puthucheary 2013; Romero-Bermejo 2011). Survivors of
sepsis report persistent problems that can last for years after hospi-
tal discharge. About 50% to 70% of sepsis survivors report phys-
ical alterations (weakness and dyspnoea), psychological problems
(post-traumatic stress syndrome and depression), and cognitive
(poor concentration and memory loss) and social issues (delayed
return to work and loss of earnings) (Dowdy 2005). Manage-
ment of septic stages remains a daily challenge for clinicians. Early
administration of effective intravenous antimicrobials is highly
recommended due to their association with reduced mortality
(Castellanos-Ortega 2010; Ferrer 2009).
Index test(s)
Interleukin-6 (IL-6) is a cytokine secreted by immune cells, such
as activated monocytes and macrophages, adipocytes, and en-
dothelial cells, and it mediates a wide range of biological activi-
ties (Tanaka 2014; Thompson 2012). Some studies have shown
that cytokines such as IL-1 and tumour necrosis factor (TNF) in-
duce a state of shock with haemodynamic and haematologic al-
terations, which are classic characteristics of septic stages (Carson
1999; Dinarello 1997; Hauptmann 1991; van der Poll 1990).
Both IL-6 and IL-1 play a role in the stimulation of the synthesis
of the adrenocorticotropic hormone in the pituitary gland. They
induce the synthesis of neuronal growth factor and regulate the
growth and development of haematopoietic cells and embryonic
stem cells (Song 2005). In addition, IL-6 is an endogenous py-
rogen that plays a role in systemic changes associated with in-
fection, tissue injury and in the stimulation of hepatic protein
synthesis during acute-phase responses (Kishimoto 1995). Inter-
leukin-6 concentrations can be measured in blood samples at dif-
ferent times during hospitalization (Thompson 2012); however,
IL-6 measurement in other biological fluids has been suggested
as potentially useful for diverse pathological conditions, Heney
1995, including cerebrospinal (Takahashi 2014), pleural (Thomas
2016), and peritoneal fluids (Cheong 2002). In healthy adults,
IL-6 plasma concentrations range from 0.2 to 7.8 pg/mL, while
IL-6 concentration in adults with sepsis can exceed 1600 pg/mL
(Thompson 2012). Clinical response and the severity of infection
affect the values of IL-6 in adults, but this relationship is not clear
in children (Aneja 2011). On the contrary, IL-6 concentrations
in newborns have been estimated at between 18 to 26 pg/mL,
with a significant decrease during the first few years of life without
the presence of infection (Song 2005). In addition, some authors
have reported elevated concentrations of IL-6 in paediatric burn
patients without sepsis (Finnerty 2007).
Clinical pathway
Since the 2015 sepsis consensus, the underlying organ dysfunction
is identified as an acute change in total SOFA score ≥ 2 points
due to the infection, and immediate treatment is highly recom-
mended (Singer 2016). Management of patients with suspected
sepsis includes volume resuscitation, a collection of samples for
microbiological diagnosis, early antimicrobial therapy, and infec-
tion source control (Dellinger 2013; Rhodes 2017; Singer 2016).
Current clinical practice guidelines recommend administration
of empiric antimicrobial therapy, including one or more drugs
that have activity against most pathogens (Dellinger 2013; Green
2008; Levy 2018; Reinhart 2010; Rhodes 2017). However, one
consequence of this strategy is the overtreatment of patients with
non-infectious diseases, which can induce antimicrobial resistance
and increased economic costs. The use of biomarkers for early di-
agnosis and to guide empiric antimicrobial agents has only been
suggested as supplementary data to clinical assessment, in cases of
difficult-to-culture pathogens, or in clinical situations where the
suspected infection is unclear (Dellinger 2013; Rhodes 2017).
Prior test(s)
No prior tests for the diagnosis of sepsis have been proposed. The
basis of future tests, including blood tests and microbiological
cultures, lies in the identification of signs of inflammation and/
or end-organ hypoperfusion by a clinical assessment (Dellinger
2013; Rizoli 2002).
Role of index test(s)
At present, sepsis is defined as a suspected or documented infection
accompanied by an acute increase of the quick Sequential Organ
Failure Assessment (qSOFA) scores (Singer 2016). For years, cul-
tures have been essential to document the presence of an infection,
though their results can take 24 to 48 hours (Levy 2003). In addi-
tion, the results of the cultures may be undeterminable due to the
use of an empiric antimicrobial before the sampling or difficult-
to-culture pathogens (Dellinger 2013; Rhodes 2017). Biomarkers
used for the diagnosis of sepsis may provide faster results in com-
parison with microbiology tests, resulting in a quicker initiation
of treatment (Boucher 1999). Interleukin-6 appears to be a me-
diator of sepsis, and its secretion is rapidly induced in the course
of acute inflammatory reactions (Song 2005). Most patients with
sepsis have increased plasma levels of IL-6 at their admission to
the ICU (Waage 1989). High IL-6 levels have been directly asso-
ciated with risk of death, especially death caused by intra-abdom-
inal sepsis (Patel 1994). Likewise, an association between mean
plasma IL-6 concentration over time and mortality rate has been
shown. Persistent elevation of IL-6 appears to be more important
than that of the initial or peak levels in terms of outcome (Pinsky
1993). Interleukin-6 could be considered as a potential triage test
of sepsis, in order to ensure quick initiation of empirical antibiotic
management in critically ill patients who are waiting for culture
results. In addition, if the detection of IL-6 levels demonstrates
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high specificity and sensitivity towards sepsis, it might play an
important role in replacing other diagnostic tools, thus reducing
unnecessary patient exposure to antibiotics (Gentile 2013).
Alternative test(s)
Currently, several biomarkers that may have the ability to improve
early recognition and decrease the severity of sepsis have been eval-
uated. For example, the use of C-reactive protein concentrations
has been proposed as an acute-phase reactant for the diagnosis of
bacterial infections, as well as a factor that can lead to a reduction in
the mortality rate of septic patients (Andriolo 2017; Onyenekwu
2017; Simon 2004). A C-reactive protein level that exceeds 0.8
mg/L is abnormal and may indicate the presence of an inflamma-
tory process. Likewise, the diagnostic value of procalcitonin has
been evaluated in several systematic reviews, with contradictory
results (Simon 2004; Tang 2007; Wacker 2013). Other biomark-
ers, such as IL- 8, Livaditi 2006, and soluble triggering receptor
expressed on myeloid cells 1 (sTREM-1), Gamez-Diaz 2011, have
also been evaluated, without conclusive results (de Montmollin
2014).
Rationale
Currently, the World Health Organization (WHO) recognizes
sepsis as a healthcare priority, and it urges the Member States to
include and reinforce the prevention, diagnosis, and treatment of
this condition in national health systems (WHO 2017). Despite
the fact that sepsis is one of the leading causes of mortality in
critically ill patients, it lacks an accurate diagnostic test (Bloos
2014). The differentiation of sepsis from other syndromes is es-
sential in order to avoid unnecessary administration of antibiotics
and to start appropriate therapy sooner. Some authors have re-
ported higher levels of IL-6 in patients with sepsis and multiple
organ dysfunction, but not in other conditions, such as trauma or
cardiac arrest (Bloos 2014; Song 2005). The detection of higher
IL-6 levels could therefore be potentially useful in early diagnosis
(Jekarl 2015). Determining the accuracy of the detection of IL-
6 levels as a biomarker for the diagnosis of sepsis might help to
provide adequate and timely management of critically ill patients.
This could reduce the morbidity and mortality associated with
sepsis. Furthermore, an accurate measurement tool may also limit
hospitalization costs and potential antimicrobial resistance. This
current review focused on one biomarker (IL-6) only, and did not
include comparisons of diagnostic accuracy with other biomark-
ers, as there is a Cochrane Review in process assessing the roles of
C-reactive protein, procalcitonin, and presepsin as biomarkers for
sepsis (Onyenekwu 2017).
O B J E C T I V E S
To determine the diagnostic accuracy of plasma interleukin-6 (IL-
6) concentration for the diagnosis of bacterial sepsis in critically
ill adults.
Secondary objectives
• To explore the effects of different thresholds in the accuracy
of IL-6 for the diagnosis of sepsis.
• To determine whether the pathological source of sepsis (i.e.
pneumonia, bacteraemia, urinary infections, among others) or
other prespecified sources affect the accuracy of plasma IL-6
concentration as a diagnostic tool.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered diagnostic test accuracy studies that included pa-
tients aged 18 years or older with suspicion of sepsis during their
hospitalization, and where IL-6 levels were evaluated by serologi-
cal measurement, as well as sepsis confirmation by means of clin-
ical diagnosis and/or identification of microbiological pathogens
in cultures. Studies should have provided information about the
specificity and sensitivity of the results. We considered abstracts
and conference proceedings in the initial selection of references.
However, due to these selected references not providing enough
information for the assessment of themethodological quality, they
were classified as studies awaiting classification. We excluded be-
fore-after studies, case-control studies (see Differences between
protocol and review), and case reports.
Participants
We included studies evaluating critically ill adults aged 18 years or
older under suspicion of sepsis (i.e. fulfilling SIRS criteria). These
studies included participants from different clinical settings, such
as emergency departments, hospital wards, and ICUs.We excluded
studies of neonatal or paediatric patients with suspicion of sepsis.
Index tests
We included articles with a description of the index test for the
measurement of IL-6 in plasma as a sign of systemic inflammatory,
metabolic, and physiologic activity. Measurement of IL-6 concen-
trations should have been performed before initiation of empiri-
cal antibiotic treatment. We excluded measurements of IL-6 other
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than serum (i.e. pleural effusion, peritoneal fluid, or cerebrospinal
fluid).
Target conditions
As we mentioned earlier in the Background section of this report,
for years sepsis was considered to be a systemic inflammatory re-
sponse syndrome of the host due to an infection (Appendix 1)
(Levy 2003). Recently, a consensus task force of the European
Society of Intensive Care Medicine (ESICM) and the Society of
Critical Care Medicine (SCCM) updated the definition of sepsis
and septic shock to be defined as a life-threatening organ dysfunc-
tion resulting from a dysregulated host response to inflammation
(Singer 2016).
Reference standards
The criteria used for the diagnosis of sepsis have been modified
from the initial proposals by Bone and colleagues in 1991 (Bone
1992), which were endorsed by the American College of Chest
Physicians (ACCP) and the SCCM, to those developed in 2015
by the SCCM and the ESICM (Singer 2016). A full description
of the mentioned definitions and clinical criteria can be found in
Appendix 1, Appendix 2, and Appendix 3. Briefly, the following
three sets of criteria have been used over the years.
• 1991 ACCP/SCCM criteria (Bone 1992): these criteria
were the first attempt to provide a conceptual framework to
diagnose, monitor, and treat sepsis. In addition, this consensus
was the first to introduce the term ’systemic inflammatory
response syndrome’ (SIRS), broadly defined as all findings
associated with systemic activation of the innate immune
response. Sepsis is defined under Bone 1992 as SIRS plus signs
of infection, while severe sepsis is considered to be any sepsis
associated with organ dysfunction, hypoperfusion, or
hypotension.
• 2001 SCCM/ESICM/ACCP/ATS/SIS criteria (Levy 2003):
the 2001 consensus conference reviewed the strengths and
weaknesses of the 1992 criteria, and developed modified criteria
incorporating the latest clinical understanding of sepsis, as well
as findings of clinical trials. These criteria highlighted the role of
systemic inflammation in response to an infection, broadly
defined as a pathological process induced by a micro-organism
(Levy 2003). Sepsis was then defined as a systemic inflammatory
response syndrome of the host due to an infection (Levy 2003).
• 2015 SCCM/ESICM criteria (Singer 2016): sepsis is
defined under Singer 2016 as a life-threatening organ
dysfunction caused by a dysregulated host response to infection.
For clinical cases, organ dysfunction can be defined by an
increase in the Sequential Organ Failure Assessment (SOFA)
score of 2 points or more. In addition, septic shock is considered
as a subset of sepsis in which particularly profound circulatory,
cellular, and metabolic abnormalities are associated with a greater
risk of mortality. Under Singer 2016, terms such as SIRS and
severe sepsis are no longer recommended in the management of
this condition.
A common element to all these criteria is the requisition of cultures
to document the suspected infection, however positive findings
are not a requirement for antibiotic management (Bone 1992;
Levy 2003; Singer 2016). We considered all these criteria as valid
reference standards for sepsis, recognizing that the knowledge in
this field is still evolving.
Search methods for identification of studies
Electronic searches
We searched the following databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2019, Issue 1, Appendix 4);
• MEDLINE via Ovid SP (1956 to 25 January 2019,
Appendix 5);
• Embase via Ovid SP (1982 to 25 January 2019, Appendix
6);
• LILACS (Latin American and Caribbean Health Science
Information database) via BIREME (1982 to 25 January 2019,
Appendix 7);
• Web of Science Indexes (Science Citation Index Expanded
(SCI-EXPANDED), Social Sciences Citation Index (SSCI), Arts
& Humanities Citation Index (A&HCI), Emerging Sources
Citation Index (ESCI); from inception to 25 January 2019,
Appendix 8).
We designed structured search strategies using controlled search
terms appropriate for each database as well as free-text search terms
as outlined in the Cochrane Handbook for Systematic Reviews of
Diagnostic Test Accuracy (Deeks 2013). We did not use search fil-
ters (collections of terms aimed at reducing the number needed
to screen) as an overall limit because in those reviews that have
used them they have not proved to be sensitive enough (Whiting
2011a).We did not apply any language restriction to the electronic
searches.
Searching other resources
We screened the reference lists of all relevant papers for additional
studies and searched for similar articles related to the final included
studies. We contacted relevant authors for further details about
studies, but we did not receive replies from the contacted authors
at the time of review publication (see Results of the search).We did
not perform handsearching, as there is little published evidence of
the benefits of handsearching for reports of diagnostic test accuracy
studies (Glanville 2012).
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Data collection and analysis
Selection of studies
Two review authors (IAR, DMF) independently identified poten-
tially eligible studies based on title and abstract. Any disagreements
were resolved by discussing the paper(s) in question with a third
review author (MR). We retrieved the full-text copy of each study
assessed as potentially eligible, and two review authors indepen-
dently evaluated the full texts for inclusion or exclusion according
to the selection criteria. We documented the study selection pro-
cess in a PRISMA flow diagram.
Data extraction and management
Four review authors (DMF, IAR, XN, NM) extracted the study
characteristics from each included study, including data on quality
assessment and investigation of heterogeneity, and transferred this
information into a study-specific format, as described in Appendix
9. Any disagreements were resolved by discussion with a third re-
view author (JZ or MR). We cross-tabulated the numerical in-
formation from the index test results (positive or negative) in 2
x 2 tables against the target disorder (positive or negative), and
presented the results in tables (Appendix 10).
Assessment of methodological quality
Four review authors (NM, JZ, MR, IAR) independently and in
duplicate assessed the methodological quality using the Quality
Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool
(Whiting 2011b), as recommended by theCochrane Handbook for
Systematic Reviews of Diagnostic Test Accuracy (Deeks 2013). This
tool consists of four domains: patient selection, index test, refer-
ence standard, and patient flow.We assessed each domain in terms
of risk of bias, and further considered the first three domains in
terms of applicability.We reported the QUADAS-2methodologi-
cal assessment of studies using bespoke tables. Operational defini-
tions describing the use of QUADAS-2 are presented in Appendix
11. This format was piloted against 10 primary diagnostic studies
in order to standardize this assessment and to identify any possi-
ble disagreement between review authors. Any discrepancies were
resolved by discussion.
Statistical analysis and data synthesis
For all included studies we extracted data from the 2 x 2 tables
(numbers of true positives, false positives, true negatives, and false
negatives) showing the cross-classification between binary test re-
sults and the binary reference standard. For each study, we calcu-
lated sensitivities, specificities and their 95% confidence intervals
(CIs) (Appendix 10). We presented results graphically by plotting
estimates of sensitivities and specificities (both with 95% CIs) in a
forest plot and in a receiver operating characteristic (ROC) space
in order to visually assess the between-study variability. We con-
sidered these findings in light of the methodological quality of in-
dividual studies. We used the Cochrane statistical software Review
Manager 5 to document these analyses (Review Manager 2014).
We planned to obtain summary sensitivity and summary speci-
ficity estimates using the bivariate model (Reitsma 2005),
analysing information of the most common thresholds when data
with more than one positive threshold was reported within the
same study (Molano Franco 2015). However, we were unable to
perform this analysis because we observed high heterogeneity in
the data that prevented the estimation of summary accuracy esti-
mates. Instead, we estimated a summary ROC (SROC) curve by
fitting a hierarchical summary ROC (HSROC) non-linear mixed
model (Rutter 2001). Using HSROC parameter estimates, we de-
rived sensitivity at the median value of specificity along with cor-
responding 95% CIs calculated using the delta method as imple-
mented in R package. We calculated the potential numerical con-
sequences given a positive and negative IL-6 test result, using dif-
ferent prevalences. All analyses were conducted in the SAS statisti-
cal software package, SAS 2014, and R software (R Development
Core Team 2008). This is a diversion from the protocol that is
explained in the Differences between protocol and review section.
Investigations of heterogeneity
We initially investigated heterogeneity by visual examination of
forest plots of sensitivities and specificities and through visual ex-
amination of individual study results in the ROC space. Antici-
pated sources of heterogeneity included the year of publication,
country/geographical area, setting (emergency, ICUs, hospitaliza-
tion ward, or other), baseline diagnosis, the origin of infection
(pneumonia, urinary infection, meningitis), type of sepsis (severe,
septic shock), and type of reference standard. Asmentioned above,
we estimated an SROCcurve by fitting anHSROC (Rutter 2001),
and explored the effect of predefined sources of heterogeneity on
model parameters. When possible, we investigated the effect of
covariates by including each potential source of heterogeneity, one
at each time, in the original HSROCmodel. We initially explored
whether therewas a significant difference in the shape of the SROC
curve. If we ruled out a significant effect of the covariate on the
shape of the curve, we then analysed whether the covariates af-
fected both accuracy and threshold parameters of the model, or
either. Conversely, if the shape varies with the covariate, no further
simplifications of themodel can be performed.We used likelihood
ratio tests to compare models with and without the corresponding
covariates effects on shape, accuracy and threshold.We conducted
all these analyses using the SAS statistical software package (SAS
2014). This is a diversion from the protocol that is explained in
the Differences between protocol and review section.
Sensitivity analyses
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We planned to examine the robustness of the meta-analyses by
conducting sensitivity analyses. Our primary analysis included all
studies; sensitivity analysis would exclude studies at high risk of
bias or studies for which there were important concerns about po-
tential applicability. However, since we judged all included studies
as at high risk of bias due to index test issues, this analysis could
not be performed. This is a diversion from the protocol that is
explained in the Differences between protocol and review section.
Assessment of reporting bias
Quantitative methods for exploring reporting bias are not well
established for diagnostic test accuracy studies.Wedidnot perform
a formal assessment of publication bias using methods such as
funnel plots or regression tests because such techniques have not
been useful for diagnostic test accuracy studies (Deeks 2013). This
is a diversion from the protocol that is explained in theDifferences
between protocol and review section.
R E S U L T S
Results of the search
The details of our search and selection process are shown in Figure
1. The electronic database searches yielded 41,588 references from
selected databases after removal of duplicates. We searched for pri-
mary studies through other resources but did not find additional
potentially eligible studies. Our initial screening of titles and ab-
stracts identified 108 references to assess in full text. We excluded
65 of the 108 full-text studies for the following reasons: a) no re-
porting of accuracy data for IL-6; b) focus was on the prediction of
sepsis; c) case-control studies; d) other reasons (see Characteristics
of excluded studies). We classified 20 conference proceedings that
contained insufficient information to apply all of the selection cri-
teria, as well as to perform a full data extraction, as studies awaiting
classification (see Characteristics of studies awaiting classification).
We included 23 studies in the qualitative synthesis (Aalto 2004;
Anand 2015; Du 2003; Endo 2012; Fu 2013; Gao 2018; Gomez
2010; Harbarth 2001; Hou 2016; Jekarl 2013; Jiang 2015; Li
2013; Liu 2005; Llewelyn 2013; Mat-Nor 2016; Meynaar 2011;
Moscovitz 1994; Ramirez 2009; Sakr 2008; Tromp 2012; Tsalik
2012; Tsantes 2013; Zhao 2014). However, because we were un-
able to rebuild the 2 x 2 table in two studies (we contacted the au-
thors of Gao 2018 andHou 2016 by email, but at the time of pub-
lication of this review had not received replies), we only included
21 studies in the main quantitative analysis (Aalto 2004; Anand
2015; Du 2003; Endo 2012; Fu 2013; Gomez 2010; Harbarth
2001; Jekarl 2013; Jiang 2015; Li 2013; Liu 2005; Llewelyn 2013;
Mat-Nor 2016; Meynaar 2011; Moscovitz 1994; Ramirez 2009;
Sakr 2008; Tromp 2012; Tsalik 2012; Tsantes 2013; Zhao 2014).
In addition, we contacted the main author of Harbarth 2001 by
email to confirm the use of threshold to define sepsis, but at the
time of the analysis had not received a reply. We included this
study with the reported cut-off transformed to pg/mL (Harbarth
2001; 200,000 pg/mL).
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Figure 1. Study flow diagram.
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Characteristics of included studies
Details of the population, index test, target condition, and ref-
erence standard for the 23 included studies are provided in the
Characteristics of included studies table. The main characteristics
of the included studies are summarized in Table 1.
General characteristics
We included a total of 23 studies and 4192 critically ill adults in the
qualitative analysis. The sample size ranged from 20, in Ramirez
2009, to 652 ill adults, inZhao 2014.Mean sample sizewas 167.68
participants (interquartile range (IQR): 66 to 231). The included
studies were published between 1994 and 2018. Most studies were
published after the sepsis consensus of 2001, but before the release
of the 2015 consensus criteria (16 studies; 69.5%; Anand 2015;
Endo 2012; Fu 2013; Gomez 2010; Harbarth 2001; Jekarl 2013;
Jiang 2015; Li 2013; Llewelyn 2013; Meynaar 2011; Ramirez
2009; Sakr 2008; Tromp 2012; Tsalik 2012; Tsantes 2013; Zhao
2014). The three studies published after 2015 did not apply the
updated definition (Gao 2018; Hou 2016; Mat-Nor 2016). A
considerable number of studieswere performed inAsia (12 studies;
52.1%), with China being the country with the most studies (8
studies; Du 2003; Fu 2013; Gao 2018; Hou 2016; Jiang 2015;
Li 2013; Liu 2005; Zhao 2014). Nine studies were performed
in Europe, and only two studies were conducted in the USA (
Moscovitz 1994; Tsalik 2012).
All studies provided information about participants with sepsis
versus patients under suspicious of sepsis (i.e. SIRS adult patients).
In addition, some studies provided data from healthy controls, but
we did not include this information in the review. Four studies us-
ing the 2001 criteria provided additional information about sepsis
versus SIRS plus organ dysfunction (Llewelyn 2013), severe sep-
sis versus SIRS (Sakr 2008), severe sepsis and shock versus SIRS
(Jekarl 2013), and septic shock versus SIRS (Gomez 2010). Most
of the studies were funded by academic, governmental, or institu-
tional sources (11 studies; 47.8%). Three studies were funded by
medical device companies (Gomez 2010; Llewelyn2013;Meynaar
2011), and three other studies stated that no funds were received
for their development (Li 2013; Tromp 2012; Tsantes 2013).
Population
The age of the participants was heterogeneously reported; seven
studies reported mean age for all enrolled participants, ranging
from 45.1 to 66 years (Aalto 2004; Du 2003; Jekarl 2013; Jiang
2015; Mat-Nor 2016; Meynaar 2011; Sakr 2008). The percent-
age of included men ranged from 37%, in Moscovitz 1994, to
77%, in Llewelyn 2013. The included studies reported multiple
baseline diagnoses, with most studies only referring to their par-
ticipants as ill patients, ICU patients, or patients with suspected
sepsis (19 studies; 82.6%). Four studies were developed in specific
populations, such as patients with acute respiratory distress syn-
drome (ARDS) (Tsantes 2013), biliary and intra-abdominal in-
fections (Jiang 2015), haematological malignancies (Fu 2013), or
mechanically ventilated patients (Ramirez 2009). Thirteen stud-
ies (56.5%) reported basal measurements of the Acute Physiology
AndChronicHealth Evaluation (APACHE-II in most cases), with
mean APACHE in septic groups ranging from 9.3 to 25.8 units.
The origin of the infection was heterogeneous in the enrolled
samples, and included acute pyelonephritis, pneumonia, diges-
tive tract infection, intra-abdominal infection, urosepsis, celluli-
tis, lower respiratory tract infections, urinary tract infections, and
bloodstream infections, among others. The included studies did
not provide subgroup information by source of infection. Four
studies assessed bacteraemia (Aalto 2004; Fu 2013; Moscovitz
1994; Tromp 2012). One study focused its main analysis on the
comparison between sepsis by culture findings (positive or nega-
tive) versus SIRS (Anand 2015).
The most common setting was ICUs (mixed and surgical) (13
studies; Anand 2015; Du 2003; Gomez 2010; Harbarth 2001;
Hou 2016; Li 2013; Liu 2005; Llewelyn 2013; Mat-Nor 2016;
Meynaar 2011; Ramirez 2009; Sakr 2008; Tsantes 2013). The
remaining studies were set in emergency departments, with the
exception of three studies for which the setting was unclear (Fu
2013; Gao 2018; Jiang 2015). The use of empirical antibiotics was
not explicitly stated or was unclear in 13 studies; in nine studies
antibiotics were administered after blood sampling (Aalto 2004;
Harbarth 2001; Hou 2016; Jekarl 2013; Jiang 2015; Li 2013; Liu
2005; Moscovitz 1994; Ramirez 2009). In one study, participants
were excluded if they had received antimicrobial treatment for
more than 24 hours before blood sampling (Mat-Nor 2016).
Index test
All but five of the included studies, Endo 2012; Gao 2018; Hou
2016; Li 2013; Llewelyn 2013, reported IL-6 as the main test
assessed. Fourteen studies used automated immunoassay analysers,
and the remaining studies used enzyme-linked immunosorbent
assay (ELISA) kits (Du 2003; Jiang 2015; Li 2013; Liu 2005;
Llewelyn 2013; Mat-Nor 2016; Moscovitz 1994; Ramirez 2009;
Zhao 2014). Themethods/techniques used to read the results were
absorbance/optical density (6 cases;Du 2003; Jiang 2015; Li 2013;
Mat-Nor 2016; Ramirez 2009; Zhao 2014); chemiluminescence
(8 cases; Aalto 2004; Anand 2015; Endo 2012; Gomez 2010;
Harbarth 2001; Meynaar 2011; Sakr 2008; Tromp 2012); and
electrochemiluminescence (6 cases; Fu 2013; Gao 2018; Hou
2016; Jekarl 2013; Tsalik 2012; Tsantes 2013).
The threshold of positivity for sepsis ranged from 40 pg/mL, in
Tsalik 2012, to 200,000 pg/mL, inHarbarth 2001.Only one value
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(100 pg/mL) was reported by more than one study (Endo 2012;
Tsalik 2012). Llewelyn 2013 analysed the threshold of 200 pg/
mL for sepsis versus SIRS and for sepsis versus SIRS with organ
dysfunction. In addition, Tsalik 2012 provided information about
three different cut-offs comparing sepsis versus SIRS patients (40,
100, and 500 pg/mL). No threshold was prespecified before sta-
tistical analysis (see Characteristics of included studies). Llewelyn
2013 also reported undetermined results for assessed groups; no
additional studies reported these results.
Reference standard
Ten studies used the 1991 ACCP/SCCM Consensus Conference
Committee to define sepsis (Bone 1992; 40.9%; Du 2003; Gao
2018;Harbarth 2001; Jekarl 2013; Jiang 2015; Li 2013; Liu 2005;
Meynaar 2011; Sakr 2008; Tsalik 2012). In addition, six studies
used the 2001 SCCM/ESICM/ACCP/ATS/SIS sepsis definition
conference (27%; Anand 2015; Gomez 2010; Llewelyn 2013;
Mat-Nor 2016; Tsantes 2013; Zhao 2014). Sepsis was diagnosed
by critical care, emergency, or internal medicine clinicians in five
studies (Anand 2015; Li 2013; Mat-Nor 2016; Sakr 2008; Tsalik
2012), while this information was either unclear or not stated in
the remaining studies.
Sepsis prevalence ranged from 12.2%, in Aalto 2004, to 77.9%, in
Gomez 2010. In 12 studies the prevalence of sepsiswas greater than
50% (Anand 2015; Endo 2012; Gomez 2010; Harbarth 2001;
Jekarl 2013; Jiang 2015; Li 2013; Llewelyn 2013; Mat-Nor 2016;
Tsalik 2012; Tsantes 2013; Zhao 2014). The median estimated
prevalence was 47% (IQR: 37 to 69).
Methodological quality of included studies
We appraised the quality of primary diagnostic accuracy studies
using the QUADAS-2 tool. The overall risk of bias and applica-
bility concerns of the studies are summarized in Figure 2. Qual-
ity assessment results for individual studies are presented in the
Characteristics of included studies tables and in Figure 3.
Figure 2. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies.
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Figure 3. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study.
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Due to concerns related to the source of participants, we judged
the risk of bias of patient selection (QUADAS-2, domain 1) to
be high in one study (Tsalik 2012). We considered eight trials to
have an unclear risk of bias for this domain, mostly due to insuf-
ficient information related to the patient sampling (consecutive
or random), as well as insufficient information about exclusions
(Aalto 2004; Anand 2015; Endo 2012; Gao 2018; Hou 2016;
Jiang 2015; Moscovitz 1994; Tsantes 2013). We considered the
remaining 14 studies to be at low risk of bias. We had few concerns
about applicability in most of the included trials. However, we
had concerns about five studies that focused on specific popula-
tions, that is culture-negative septic patients (Anand 2015), intra-
abdominal infections (Jiang 2015), ventilator-associated pneumo-
nia patients (Ramirez 2009), a mix of cohorts of previous studies
(Tsalik 2012), or ARDS patients (Tsantes 2013).
Regarding the index test assessment (QUADAS-2, domain 2), we
considered all studies to be at high risk of bias because none of
them used a prespecified cut-off to estimate sensitivity/specificity
of IL-6 (Figure 3; Figure 2). Likewise, most of the studies did not
provide sufficient information to enable us to determine if index
test results were interpreted without prior knowledge of the results
of the reference standard. However, IL-6 results were probably
performed automatically and were thus not affected by additional
information. We had minor concerns about the applicability of
index tests in all of the included trials.
We judged risk of bias due to conduct or interpretation of the
reference standard(s) (QUADAS-2, domain 3) to be unclear in
eight studies (Gomez 2010; Hou 2016; Jekarl 2013; Jiang 2015;
Liu 2005; Moscovitz 1994; Tsantes 2013; Zhao 2014). This was
due to a lack of information about whether the reference standard
results were interpreted with, or without, prior knowledge of the
results of the IL-6 measurements. We considered the risk to be low
for the remaining 15 studies. We considered applicability of this
domain to be low in all cases.
Finally, with regard to the flow and timing assessment (QUADAS-
2, domain 4), we considered four studies to have an unclear risk of
bias because there was insufficient information about the interval
between IL-6 measurement and the application of the reference
standard, as well as the exclusion of participants from the final
analysis of accuracy (Gao 2018; Llewelyn 2013; Moscovitz 1994;
Tromp 2012).
Findings
We included 21 studies collecting information from 1894 septic
cases and 1756 non-septic cases in the main analysis (Figure 4).
For this analysis, we excluded data for other comparisons provided
by studies, including severe sepsis versus septic shock; severe sepsis
versus SIRS; and shock versus SIRS. In addition, we selected one
of the groups/thresholds reported by Anand 2015 (positive-cul-
ture group) and by Tsalik 2012 (threshold of 100 pg/mL), since
these groups were also found in other included studies. The range
of sensitivities and specificities estimated by study, as well as the
different thresholds proposed to define IL-6 positive findings, are
shown in Figure 4. The SROC curve under the HSROC model,
representing the accuracy of plasma IL-6 thresholds used across
studies, as well as individual study accuracy estimates, are shown in
Figure 5. Given the considerable variation in collected data shown
by Figure 5, and considering the heterogeneity of data described
in the Results of the search section, we refrained from calculating
a formal sensitivity and specificity summary.
Figure 4. Forest plot of 1 Plasma interleukin-6 concentrations.
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Figure 5. Summary receiver operating characteristic (SROC) plot of plasma interleukin-6 concentrations,
using hierarchical SROC parameters (estimated with SAS statistical software package).
We used the HSROC parameters to illustrate variations in sen-
sitivity under a fixed specificity. Using a prevalence of sepsis of
50% and a fixed specificity of 74%, the estimated sensitivity was
66% (95% confidence interval (CI) 60 to 72). We noticed that
10 out of 21 individual studies included in this analysis reported
sensitivities inferior or equal to this estimation. In terms of the
possible consequences in a population of 1000 adult patients un-
der suspicion of sepsis, this would translate into:
• 330 out of 1000 patients would receive appropriate and
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timely antibiotic therapy;
• 130 out of 1000 patients would be wrongly considered to
have sepsis, and would receive unnecessary antibiotic therapy,
with the added risk of resistance in a hospital setting, and may
suffer delays in receiving appropriate treatment for their
situation;
• 370 out of 1000 patients would avoid unnecessary
antibiotic therapy;
• 170 out of 1000 patients would have undiagnosed sepsis
and would be at serious risk of further morbidity and death due
to delays of immediate antibiotic treatment.
Additional estimations with prevalences of 12% and 78% (min-
imum and maximum values from included studies) show an in-
crease in the number of false positives or false negative, respectively
(Summary of findings).
Investigation of heterogeneity
Due to the considerable variability of collected data, which pre-
vented us from performing subgroup analysis (i.e. baseline diag-
nosis or origin of infection; see Differences between protocol and
review), we were not able to evaluate the potential effect of several
sources of heterogeneity as initially planned. We were able to as-
sess the effect of three covariates: year of publication (studies pub-
lished in or after the year 2011; see Differences between protocol
and review), country/geographical area (studies conducted in Asia
versus other settings) and setting (emergency versus ICU). We did
not find statistical evidence of a difference in shape, test accuracy,
or threshold parameters for models including country and setting
as covariables. We found differences regarding shape and accuracy
parameters according to publication year (Likelihood ratio test =
7.91; df = 2; P = 0.019). Approximately half of the studies pub-
lished after 2011 showed specificities lower than 70%, while none
of the studies published before 2011 showed specificities lower
than 70% (Figure 6).
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Figure 6. Investigation of heterogeneity: year of publication (≥ 2011).
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D I S C U S S I O N
Summary of main results
We included 23 studies (4192 critically ill adult patients) assess-
ing the accuracy of plasma IL-6 concentrations for the diagnosis
of sepsis. The included studies enrolled patients under suspicion
of sepsis (i.e. SIRS patients), with further confirmation of sepsis,
severe sepsis, septic shock, or no infection. The samples were het-
erogeneous in terms of their distribution of age, gender, main di-
agnosis, setting, country, positivity threshold, sepsis criteria, year
of publication, and origin of infection, among other factors. In
addition, the prevalence of sepsis reported in the included studies
varied widely (from 12% to 78%; median: 47.3%).
The main results of plasma IL-6 concentration as a biomarker are
provided in the Summary of findings. This biomarker was assessed
using a considerable number of thresholds that were not prespeci-
fied (from 40 to 200,000 pg/mL). We considered all studies to be
at high risk of bias (QUADAS-2/index test domain). The SROC
curve showed a great dispersion in individual studies accuracy es-
timates (21 studies, 3650 adult participants), therefore the consid-
erable heterogeneity in the collected data prevented us from calcu-
lating formal accuracy estimates. Using a fixed prevalence of sepsis
of 50% and a fixed specificity of 74%, we found a sensitivity of
66% (95% CI 60 to 72). If we test a cohort of 1000 adult patients
under suspicion of sepsis with IL-6, we will find that 330 patients
would receive appropriate and timely antibiotic therapy,while 130
patients would be wrongly considered to have sepsis. In addition,
370 out of 1000 patients would avoid unnecessary antibiotic ther-
apy, and 170 patients would have been undiagnosed of sepsis. This
numerical approach should be interpreted with caution due to the
limitations described above. Due to the severe consequences of
sepsis regarding its associated morbidity and mortality, we con-
sider that the number of patients without adequate treatment, as
a consequence of IL-6 results, can be considered as unacceptable
and deleterious for daily clinical management of this target condi-
tion (Summary of findings). Heterogeneity of data was not fully
explained for any of the covariates investigated within this review.
Strengths and weaknesses of the review
The strengths of this review include a comprehensive literature
search performed to identify all relevant studies, a rigorous assess-
ment of the risk of bias of included studies using the QUADAS-
2 tool, as well as duplicate data extraction. We did not impose
restrictions on population characteristics such as age, site of in-
fection, or setting. As a result, we found a highly heterogeneous
body of evidence, with the included studies presenting differences
in baseline diagnosis, origin of infection, reference standard ap-
plied, and prevalence of sepsis in their participants, among other
factors. We tried to explore and quantify the possible sources of
heterogeneity, but most of the assessed factors failed to explain
the observed variability. Only one covariate (year of publication≥
2011) affected the accuracy and shape parameters of the HSROC
model. We analysed this variable following the suggestions of the
peer reviewers of the review, in order to assess if the most recent
evidence reflects a better IL-6 performance (Differences between
protocol and review). Approximately half of the studies published
after 2011 showed specificities lower than 70%, while none of
the studies published before 2011 showed specificities lower than
70%. This fact has an impact while evaluating differences in the
shape of the curve by publication year. We cannot exclude that
other factors, such as prevalence or sepsis criteria, are involved
in this modification of effect. In addition, the sensitivity analyses
planned in our protocol, Molano Franco 2015, based on the ’Risk
of bias’ assessments were made redundant by the serious risk of
bias introduced by the threshold issues in the index test domain
(See Differences between protocol and review). Due to this high
variability that was not fully explained, we refrained from calcu-
lating a summary sensitivity and specificity.
Finally, we attempted to conduct a comprehensive search for stud-
ies, but the fact that a significant number of potentially eligible
studies were only retrieved as conference proceedings may be con-
sidered as a source of potential bias. We expect that these studies
will be fully published when our review is updated.
Agreements and disagreements with other studies or
reviews
We identified three reviews assessing the accuracy of IL-6 in the
diagnosis of sepsis (Hou 2015; Liu 2016; Ma 2016). Ma and col-
leagues collected and pooled the results of 20 studies assessing IL-
6 in sepsis (Ma 2016), with cut-off values of IL-6 ranging between
18 and 423.5 pg/mL. The authors estimated a pooled sensitivity
of 68% (95% CI 65% to 70%) and specificity of 73% (95% CI
71% to 76%) by means of a univariate model calculated byMeta-
DiSc 1.4 (Zamora 2006). Likewise, Hou and colleagues included
six studies in their review, three of which were conducted in a
paediatric population (Hou 2015). Analysing studies in an adult
population under a random-effects model (Littenberg and Moses
method; Littenberg 1993;Moses 1993), the estimated pooled sen-
sitivity was 85% (95% CI 80% to 88%), and the estimated speci-
ficity was 62% (95% CI 55% to 68%). Cut-off values in this re-
view ranged between 40 and 145 pg/mL, and risk of bias was not
assessed. Finally, Liu and colleagues identified 22 studies address-
ing the accuracy of IL-6with amedian cut-off of 138 pg/mL (rang-
ing from 75 to 220 pg/mL) (Liu 2016). Using a bivariate mixed-
19Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
effects regression model, the authors estimated a pooled sensitivity
of 72% (95% CI 63% to 80%) and specificity of 73% (95% CI
67% to 79%). Risk of bias assessed with QUADAS-1 was affected
for issues related to blinding of test and reference standard results,
as well as uninterpretable results.
Compared with our review, these studies used a different set of
criteria to select eligible references, such as case-control studies,
paediatric populations, and data about prediction of sepsis, as well
as alternative statistical approaches to analyse the collected infor-
mation. In addition, two out of the three reviews mentioned used
QUADAS-1 or no assessment of the methodological quality for
eligible studies. In our review, we refrained from calculating a sum-
mary sensitivity and specificity due to the considerable variation
in the collected data. Due to this variability, especially that gener-
ated by threshold variations, only an HSROC approach is recom-
mendable to analyse the gathered data (Deeks 2013).
We also noticed that the three identified reviews warn about sig-
nificant heterogeneity among included studies, mostly guided by
information provided by I2 statistics, but only Liu 2016 and Ma
2016 investigated their effects through a formal statistical method
(meta-regression analysis; no further details provided). Liu and
colleagues analysed six potential sources of heterogeneity, includ-
ing publication year, age of patients, prevalence, and methodolog-
ical quality (Liu 2016). Likewise, Ma and colleagues analysed the
effect of seven factors (Ma 2016), finding that admission category,
setting, and reference standard make a significant contribution in
explaining data variability. In our review, using an HSROC ap-
proach in the analysis of sources of heterogeneity, we were unable
to fully explain the heterogeneity of data using a number of pre-
specified covariates.
Applicability of findings to the review question
Our findings show the complexity of the study of sepsis in criti-
cally ill patients, as well as the multiplicity of factors involved in
the adequate diagnosis of this life-threatening dysfunction. Due to
its close relationship with inflammatory processes, plasma inter-
leukin-6 has been proposed as a potentially useful test to identify
critical patients while microbiological confirmation is achieved.
However, we found several limitations in translating these results
into clinical practice.
One of the major issues that limits the applicability of findings to
the review question is the considerable heterogeneity in the gath-
ered evidence, which was a major constraint in our statistical anal-
ysis. The effect of some critical covariates, such as baseline diag-
nosis, cut-off value for positivity, origin of infection, and reference
standard, cannot be fully analysed by the methods stated in our
protocol. This substantial variability in sepsis research was previ-
ously noticed by Singer and colleagues (Singer 2016). The authors
of the Sepsis-3 consensus stated that the lack of a validated stan-
dard clinical criterion in this field led to important discrepancies
in the estimation of sepsis incidence and related mortality (Singer
2016). Currently, there are agreements about the need to redefine
or to abandon some terms (i.e. severe sepsis), as well as the lack
of clinical significance of extended-use criteria for the diagnosis of
sepsis (i.e. two or more SIRS criteria). None of the novel biomark-
ers suggested for the diagnosis of sepsis were formally included
in the Sepsis-3 criteria, due to the fact that they “require broader
validation before they can be incorporated into the clinical criteria
describing sepsis” (Singer 2016).
In the critical care setting, the use of biomarkers has other well-
known limitations such as the associated costs, limited availabil-
ity in low/middle-income settings, and the lack of experience of
clinicians in its use. Our findings do not suggest that the accuracy
of this biomarker is sufficient enough to assure the role of this test
in the current clinical sepsis pathway. At present, the role of IL-6,
as well as other biomarkers, is being assessed in the prediction of
severe outcomes (i.e. organ failure and mortality), under a prog-
nostic approach (McGuire 2014; Pallas 2016; Rios-Toro 2017;
Stoppelkamp 2015; Wong 2015).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our evidence assessment of plasma interleukin-6 concentrations
for the diagnosis of sepsis in critically ill adults reveals several lim-
itations. High heterogeneity of the collected evidence regarding
the main diagnosis, setting, country, positivity threshold, sepsis
criteria, year of publication, and origin of infection, among other
factors, along with the potential number of misclassifications, re-
main significant constraints for its implementation. The 20 con-
ference proceedings assessed as studies awaiting classification may
alter the conclusions of the review once they are fully published
and evaluated.
Implications for research
Further studies about the accuracy of interleukin-6 for diagnosis
of sepsis in adult patients are needed. These studies should follow
well-known methodologies for the performance of diagnostic test
accuracy (DTA) studies, including:
• the predefinition of a range of thresholds to test positivity
of this biomarker;
• adherence to recognized guidelines for reporting of DTA
studies, such as the Standards for Reporting of Diagnostic
Accuracy Studies (STARD) initiative ( equator-network.org/
reporting-guidelines/stard/);
• exploration of the diagnostic value of interleukin-6
concentrations added to other biomarkers, or as a part of a
diagnostic algorithm;
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• in addition, we suggest that future studies adopt the current
definitions and clinical criteria recommended by Singer and
colleagues in order to improve the accuracy of research in this
field (Singer 2016).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aalto 2004
Study characteristics
Patient sampling Authors included 121 acutely ill participants admitted to the emergency department between
September 1997 and November 1997. Participants suspected of having systemic infection, as deter-
mined by the treating clinician’s request for a blood culture within 24 hours of admission. Unclear
if participants were enrolled in a consecutive or random manner
People with active haematological malignancies, who had undergone surgery within the previous
6 weeks, and those in systemic immunosuppressive treatment at the time of blood sampling were
excluded
Patient characteristics and set-
ting
Authors divided the participants into 3 groups according to clinical features on admission: a) par-
ticipants with infectious focus; b) participants with acute-onset fever without focus; c) participants
with neither fever nor focus. 13 participants with positive blood cultures were considered to have a
diagnosis of bacteraemia
Index tests IL-6 concentrations were measured by a chemiluminescent immunoassay system (Immulite; Di-
agnostic Products, Los Angeles, CA, USA) with detection limits of 5 ng/L. On admission, an ad-
ditional blood sample was collected into an evacuated tube (Venoject; Terumo Europe, Leuven,
Belgium) containing citrate as an anticoagulant. Each tube was immediately pressed into thawing
ice (0 °C) to minimize phagocyte activation ex vivo. Plasma was separated by centrifugation at 4 °C
and stored in aliquots at −70 °C until use
Insufficient information to determine if index test results were interpreted without knowledge of
the results of the reference standard. However, IL-6 results were probably performed automatically
and then were not affected by additional information
Authors presented best cut-off value for accuracy data.
Target condition and reference
standard(s)
Target condition: community-acquired bloodstream infection/bacteraemia
Reference standard: SIRS criteria + microbiological evidence of local infection
Blood culture was requested within 24 hours of admission. No further details provided
Unclear if reference standard results were interpreted without knowledge of the results of the index
test
Flow and timing Blood cultures and IL-6 samples were collected simultaneously
All participants received the same reference standard.
No participants were excluded from the analysis.
Comparative
Notes Funding: not stated
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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Aalto 2004 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Aalto 2004 (Continued)
Did all patients receive a refer-
ence standard?
Yes
Low
Anand 2015
Study characteristics
Patient sampling Authors included 208 participants from a single centre in New Delhi, India, from January 2013
to May 2014. Informed consent was taken from each participant or their next of kin if participant
was unconscious or not in a fit state to give consent. Unclear if participants were enrolled in a
consecutive or random manner
Exclusion criteria were people who had received prior antibiotics, transferred from other ICUs;
having conditions that were considered lethal in the next 24 hours; postoperative; immunocom-
promised; and with malignancy. People with bilateral pneumonia (suspected viral infection) and
diagnosed tropical diseases such as malaria, dengue, Leptospira, and rickettsiae were also excluded
from the study.
Patient characteristics and set-
ting
Authors enrolled adult participants admitted from the community to the ICU and diagnosed with
non-infectious SIRS, sepsis, severe sepsis, or septic shock. Participants were divided into 3 groups: a)
non-infectious SIRS; b) culture-negative sepsis; c) culture-positive sepsis. Analyses were performed
according to findings in the cultures (positive or negative)
Index tests Blood sampleswere assayed formicrobiological culture andbiomarkers on the day of ICUadmission.
They were obtained in serum evacuated separator tubes and centrifuged for the separation of serum
and processed on the same day. IL-6 estimation was done by solid-phase Chemiluminescent Access
Immunoassay System (Beckman Coulter Inc, Brea, CA, USA)
Insufficient information to determine if index test results were interpreted without knowledge of
the results of the reference standard. However, IL-6 results were probably performed automatically
and then were not affected by additional information
Authors presented best cut-off value for accuracy data.
Target condition and reference
standard(s)
Target condition: culture positive/negative bacterial sepsis
Reference standard: presence of 2 or more signs of SIRS with/without positive cultures, defined by
4 clinicians at the time of enrolment
Culture-negative and culture-positive groups were defined once the microbiological results were
available
Unclear if reference standard results were interpreted without knowledge of the results of the index
test
Flow and timing Participant demographics, principal diagnosis, and all clinical parameters were recorded at the time
of enrolment
All participants receive the same reference standard.
No participants were excluded from the analysis.
Comparative
34Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Anand 2015 (Continued)
Notes Funding: Indian Council of Medical Research
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Unclear
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Anand 2015 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
Du 2003
Study characteristics
Patient sampling Authors included all people admitted to ICU with an expected ICU stay of more than 72 h between
October 2001 and March 2002. 51 participants with diagnosis of SIRS, sepsis, severe sepsis, or
septic shock were included for analysis. Exclusion criteria not clearly stated
Patient characteristics and set-
ting
51 ICU participants (31 males and 20 females) were evaluated. The mean age of these participants
was 64.7 ± 16.3 years; mean APACHE II score at admission was 17.4 ± 7.6. A total of 13 participants
(25%) died during hospitalization
Index tests Blood samples were taken by venipuncture (within 24 h of study inclusion) and centrifuged at
4000 rpm for 10 min before serum was frozen at−20 °C for IL-6 measurements (analysed as batch
analyses at the end of the study). IL-6 concentrations were determined with a commercially available
IL-6 EASIA test kit
Insufficient information to determine if index test results were interpreted without knowledge of
the results of the reference standard. However, IL-6 results were probably performed automatically
and then were not affected by additional information
Authors presented best cut-off value for accuracy data.
Target condition and reference
standard(s)
Target condition: sepsis
Reference standard: ACCP/SCCM criteria. Clinical investigation and classification were carried out
without knowledge of the test results of IL-6
Flow and timing Routine septic work-up (including all blood samples) was performedwithin 24 h of study inclusion.
IL-6 samples were analysed at the end of the study
All participants received the same reference standard.
No participants were excluded from the analysis.
Comparative
Notes Funding: not stated
Methodological quality
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Du 2003 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Du 2003 (Continued)
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
Endo 2012
Study characteristics
Patient sampling Authors included blood samples from 207 participants with suspicion of sepsis admitted to the
emergency roomor the ICUbetween June 2010 and June 2011.Unclear if participants were enrolled
in a consecutive or random manner. People with non-bacterial infection or suspected bacterial
infection with negative cultures were excluded
Patient characteristics and set-
ting
Participants fulfilled at least 1 of the following diagnostic criteria for SIRS:
• temperature > 38 or < 36 °C;
• heart rate > 90/min;
• respiratory rate > 20/min or PaCO2 < 32 mmHg;
• white blood cell count > 12,000 or < 4000/mm3 , or immature granulocytes > 10%.
Participants were classified into subgroups according to blood culture results
Index tests IL-6 concentrations were measured using the Immulyze 2000 assay system (Siemens Healthcare
Diagnostics, Japan) using EDTA plasma as a sample
Insufficient information to determine if index test results were interpreted without knowledge of
the results of the reference standard. However, IL-6 results were probably performed automatically,
then were not affected by additional information
Authors reported 2 cut-off values for accuracy data (not prespecified in the methods)
Target condition and reference
standard(s)
No further details were provided.
Target condition: sepsis/bacterial infectious disease
Reference standard: positive cultures and diagnosis of bacterial infection by the physician
Unclear if reference standard results were interpreted without knowledge of the results of the index
test
Flow and timing Unclear time interval between IL-6 and reference standard (high probability that samples were
collected at the same time, but this is not clearly stated)
All participants received the same reference standard.
No participants were excluded from the analysis.
Comparative
Notes Funding: not stated
Methodological quality
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Endo 2012 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
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Endo 2012 (Continued)
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
Fu 2013
Study characteristics
Patient sampling Authors revised information from 1253 cases of hospitalized patients from Sichuan University,West
China Hospital, Department of Hematology in a retrospective manner (March 2011 to October
2012). 297 participants with haematologic malignancy combined with neutropenia febrile were
analysed. People with other organ malignancies and other pathogenic micro-organisms (viruses,
fungi, parasites, etc.) were excluded
Patient characteristics and set-
ting
Authors included participants 18 years of age or older; with diagnosis of blood cancer by the West
China Hospital blood medicine; and presence of fever and granulocyte reduction. Participants were
divided into bacteraemia group and non-bacteraemia group according to the results of the blood
culture
Index tests PCT, IL-6 reagents were purchased from Roche Diagnostics Inc; the test instrument was Roche
E170 (electrochemical luminescence quantitative method). Samples for IL-6 measurement were
collected before antibiotic application
Insufficient information to determine if index test results were interpreted without knowledge of
the results of the reference standard. However, IL-6 results were probably performed automatically,
then were not affected by additional information
Authors presented best cut-off value for accuracy data (not prespecified in methods)
Target condition and reference
standard(s)
Target condition: bacteraemia in haematologic malignancies (neutropenia febrile)
Reference standard: SIRS criteria + microbiological evidence of local infection
Blood culture using the French biologicalMeridian automatic blood culture detector and supporting
reagents
Unclear if reference standard results were interpreted without knowledge of the results of the index
test
Flow and timing Unclear time interval between IL-6 and reference standard (high probability that samples were
collected at the same time, but this is not clearly stated)
All participants received the same reference standard.
No participants were excluded from the analysis.
Comparative
Notes Funding: not stated
Methodological quality
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Fu 2013 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
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Fu 2013 (Continued)
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
Gao 2018
Study characteristics
Patient sampling Plasma from 50 normal adults, 60 patients with SIRS, and 134 patients with sepsis was collected
from December 2012 to November 2013 when the patients were admitted in the first affiliated
hospital of Fujian Medical University of China
Unclear if participants were recruited in a consecutive or random manner; authors stated that a
follow-up cohort was performed (we contacted authors by email for clarification of the study design,
but at the time of review publication a reply had not been received)
No exclusion criteria are reported.
Patient characteristics and set-
ting
Plasma from 50 normal adults, 60 patients with SIRS, and 134 patients with sepsis was collected
fromDecember 2012 to November 2013 when the patients were admitted in the hospital of Fujian
Medical University of China. All patients with SIRS or sepsis were hospitalized due to complications
of major surgery; trauma; heart, lung, liver, pancreas, kidney, or gastrointestinal diseases; or systemic
infection
The diagnosis of SIRS and sepsis was based on the 1992 ACCP/SCCM consensus classification.
SIRS and septic patients were classified according to blood cultures
Patients were 59% male and 41% female. Normal adult samples were obtained from volunteers via
blood bank donations. The normal group was not included in this review
Index tests IL-6 was measured with a COBAS E601 Analyzer (Roche, Mannheim, Germany). First plasma
samples were collected 1 to 2 days prior to or on the day of blood culture. Plasma was divided into
0.5 mL/tube and stored at −80 °C until analysis
Target condition and reference
standard(s)
Target condition: sepsis, based on the ACCP/SCCM consensus classification, based on clinical
symptoms and blood culture
Reference standard: positive blood cultures, either gram-negative, gram-positive bacteria or fungi
in 12 to 72 hours after culture
Blood culture was requested within 24 hours of admission. No further details provided
Unclear if reference standard results were interpreted without knowledge of the results of the index
test
Flow and timing First plasma samples were collected 1 to 2 days prior to or on the day of blood culture
All participants received the same reference standard.
Unclear if participants were excluded from the analysis
Comparative Not stated
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Notes Funding: State Science and Technology funds (2015DFA31770); Fujian Development and Reform
Commission (FGW2014); Fujian Science and Technology Foundation (2014Y4002); Fujian Med-
ical University (0-0000-081919); Fujian Education Ministry (2013-58); and Fujian Association for
international exchange of personnel funds (W13350000137)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Did all patients receive a refer-
ence standard?
Yes
Unclear
Gomez 2010
Study characteristics
Patient sampling Authors enrolled between February 2007 and September 2007, in a prospective manner, all medical
and surgical patients older than 14 years who entered the institutional emergency room or the ICU,
as well as hospitalized patients presenting with SIRS, with suspicion of infection or septic shock
criteria. Exclusion criteria included people aged younger than 14 years of age; those who had had a
pre-hospital cardiac arrest; those with severe peripheral vascular disease defined by the presence of
diagnosed intermittent claudication or the need for revascularization surgery; those with orders of
limitation of the therapeutic effort or a diagnosis other than sepsis
Patient characteristics and set-
ting
Authors analysed information from 191 participants with SIRS (115 men and 76 women, mean
age: 62 ± 19): 28 (15%) with SIRS without infection, 99 (52%) with sepsis, 37 (19%) with septic
shock, and 27 (14%) death. The studied population consisted of 32% ICU participants and 68%
hospitalized participants
Index tests IL-6 was determined with IMMULITE 1.000 system (Siemens) by immunoquiluminiscence in
solid stage, with a sensitivity of 0.2 µg/mL. The analysis of biomarkers (PCT, IL-6, and LBP)
was performed blindly (without knowing patient evolution data, only identified by the sample
identification number) in 2 series of approximately 100 samples each
Authors reported best cut-off value for accuracy data (not prespecified in methods)
Target condition and reference
standard(s)
Target condition: sepsis
Reference standard: SCCM/ESICM/ACCP/ATS/SIS 2001 criteria
Unclear if reference standard results were interpreted without knowledge of the results of the index
test
Flow and timing Unclear time interval between IL-6 and reference standard (high probability that samples and criteria
were collected at the same time, but this is not clearly stated)
All participants received the same reference standard.
No participants were excluded from the analysis.
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Comparative
Notes Funding: BRAHMS AG and Siemens Healthcare Diagnostics (provision of kits)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
Harbarth 2001
Study characteristics
Patient sampling Authors enrolled all consecutive participants admitted with a suspected diagnosis of infection and
hospitalized in the medical and surgical ICUs of the University of GenevaHospitals over a 7-month
period. Patients were not enrolled in case of early discharge or death, withholding of life support,
or complete absence of antimicrobial treatment. At time of inclusion, participants had to be newly
admitted to 1 of the ICUs; had to have a clinically suspected infection; and had to fulfil at least 2
criteria of SIRS
Patient characteristics and set-
ting
Authors enrolled 78 adult ICU participants meeting the criteria for SIRS (n = 18), sepsis (n = 14),
severe sepsis (n = 21), or septic shock (n = 25). Infections were microbiologically proven in 44 of 60
infected participants (73%) with 53% gram-negative, 38% gram-positive bacteria, and 9% mixed
infections. Leading sources of infection were the respiratory tract (n = 38) and the intra-abdominal
space (n = 10). 23 infected participants had a documented bloodstream infection
Index tests Within 12 h after admission and study entry, whole heparinized blood was drawn via an arterial
line for cytokine measurements and daily thereafter at 6:00 A.M. during the entire ICU stay until
ICU discharge or death. Blood was put on ice and plasma was collected by centrifugation at 4 °C
and stored at 70 °C until the day of assay. IL-6 was determined batch wise using commercial assays.
IL-6 measurements were performed by trained laboratory technicians blinded to the participants’
clinical course
Authors reported optimal cut-off values for accuracy data (not prespecified in methods)
Target condition and reference
standard(s)
Target condition: sepsis
Reference standard: consensus definition (Bone 1992)
Case ascertainment was done retrospectively by 2 independent investigators without knowledge of
plasma PCT, IL-6, and IL-8 values, on the basis of the review of the complete patient charts and
results of microbiologic cultures, chest radiographs, and, when available, postmortem examination
reports
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Flow and timing Case ascertainment done retrospectively on the basis of the review of the complete patient charts
All participants received the same reference standard.
No participants were excluded from the analysis.
Comparative
Notes Funding: Swiss National Science Foundation
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
Hou 2016
Study characteristics
Patient sampling Authors analysed information from 67 consecutive participants who were admitted to the Medical
ICU of SongJiang Central Hospital (Shanghai, China) over a 1-year period. Inclusion and exclusion
criteria are not clearly stated
Patient characteristics and set-
ting
24 septic participants admitted to ICU were included. The leading causes of sepsis were major
surgery, intestinal obstruction, intestinal perforation, and multiple traumas. Abdomen, thorax, and
blood were the primary sites of infection for both gram-negative and gram-positive infections. 43
SIRS participants had a mean age of 55.4 ± 10.6 years. Authors recruited 73 healthy volunteers (45
males and 28 females) with a mean age of 52.6 ± 12.9 years (not included in this review)
Index tests Blood samples were collected into clot activation additive-containing tubules, centrifuged at 1600
g for 10 minutes, followed by 16,000 g for 1 minute. Serum was collected into a clear tube and
stored at−80 °C until use. IL-6 concentrations were evaluated by electrochemical luminescence on
a Roche COBAS-e601. This is an automated heterogeneous sandwich immunoassay, with a total
assay time of 18 minutes. An IL-6 concentration higher than 7 pg/mL is considered positive
Authors reported optimal cut-off value for accuracy data (not prespecified in methods)
Target condition and reference
standard(s)
Target condition: sepsis
Reference standard: for the SIRS group, patients had to fulfil at least 2 criteria of SIRS but have
no evidence of organ dysfunction or sepsis. For the sepsis group, patients had to fulfil both the
criteria for SIRS and have microbiological evidence of local infection. Bacteria, fungi, or parasites
were cultured from the blood of all sepsis participants. SIRS participants had no symptoms of local
infection, and no micro-organisms were cultured from their blood. No additional details provided
Unclear if reference standard results were interpreted without knowledge of the results of the index
test
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Flow and timing Unclear time interval between IL-6 and reference standard (high probability that samples and criteria
were collected at the same time, but this is not clearly stated)
All participants received the same reference standard.
No participants were excluded from the analysis.
Comparative
Notes Funding: scientific foundation of Shangai scientific and technologic bureau
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
Jekarl 2013
Study characteristics
Patient sampling Authors included 177 participants (≥ 18 years of age) with diagnosis of SIRS from an emergency
department in South Korea in a prospective fashion. Patients were excluded from the study if they
showed evidence of an immunocompromised state (e.g. malignancy, HIV infection), had visited
the hospital or were discharged from the hospital within 14 days before visiting the emergency
department, or had been administered antibiotics before admission to the emergency department
Patient characteristics and set-
ting
Of the 177 enrolled cases, 99 were classified as SIRS, 62 as sepsis, and 16 as severe sepsis/septic shock.
Among the 78 sepsis and severe sepsis/septic shock participants, 70 showed infection confirmed by
bacterial growth and 8 showed suspected bacterial infections
Index tests Blood samples for IL-6 levels were drawn immediately after admission to the emergency department
and were analysed in a central laboratory within 2 h. IL-6 was measured by a chemiluminescence
method using the Elecsys IL-6 kit (Roche)
Authors reported optimal cut-off value for accuracy data (not prespecified in methods)
Target condition and reference
standard(s)
Target condition: sepsis
Reference standard: sepsis was defined as SIRS manifestation with microbial infection. Severe sepsis
was defined as sepsis associated with organ dysfunction, hypoperfusion, or hypotension. Septic
shock was defined as sepsis induced with hypotension despite adequate fluid resuscitation, along
with the presence of hypoperfusion abnormalities or organ dysfunction (Bone 1992). No further
information was available.
Unclear if reference standard results were interpreted without knowledge of the results of the index
test
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Flow and timing Unclear time interval between IL-6 and reference standard (high probability that samples and criteria
were collected at the same time, but this is not clearly stated)
All participants received the same reference standard.
No participants were excluded from the analysis.
Comparative
Notes Funding: Yeouido St. Mary’s Hospital Clinical Research Center, the Catholic University of Korea.
Sa-Gang Lab Tech Co Ltd donated IL & kits
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
Jiang 2015
Study characteristics
Patient sampling Authors collected a total of 104 serum samples from participants treated at the Department of
General Surgery,Wuhan General Hospital of Guangzhou Military Command, Wuhan, China from
May 2014 to October 2014. Unclear if the samples were collected in a consecutive or random
fashion. Exclusion criteria were not stated
Patient characteristics and set-
ting
53 participants were diagnosed with biliary infection (including cholangitis and cholecystitis) and
10 other intra-abdominal infections, as well as 26 non-infected participants diagnosed with SIRS.
An additional control group consisted of 15 healthy volunteers with no history of autoimmune,
inflammatory, or tumour disease (not included in the present review)
Index tests Blood samples were obtained from each participant at the time of admission when they were
suspected to have intra-abdominal bacterial gram-negative infection or SIRS before any treatment.
Peripheral venous blood samples were collected in tubes without additive and allowed to clot at
room temperature for 40 minutes. Serum was separated by centrifugation. All serum samples were
stored at−80 °C until tested. Serum concentrations of IL-6 were measured by ELISA (BioLegend)
Insufficient information to determine if index test results were interpreted without knowledge of
the results of the reference standard. However, IL-6 results were probably performed automatically
and then were not affected by additional information
Authors reported optimal cut-off values for accuracy data (not prespecified in methods)
Target condition and reference
standard(s)
Target condition: gram-negative bacterial sepsis
Reference standard: sepsis criteria (Bone 1992; Dellinger 2013)
Unclear if reference standard results were interpreted without knowledge of the results of the index
test
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Flow and timing Unclear time interval between IL-6 and reference standard (high probability that samples and criteria
were collected at the same time, but this is not clearly stated)
All participants received the same reference standard.
No participants were excluded from the analysis.
Comparative
Notes Funding: National Natural Science Foundation of China
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Unclear
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
Li 2013
Study characteristics
Patient sampling Authors included information from 52 consecutive adult participants (aged between 18 and 80
years) who were newly hospitalized in the 12-bed surgical ICU of the First Hospital of Sun Yat-sen
University in Guangzhou between January 2006 and October 2006. All participants had clinically
suspected infection and fulfilled at least 2 criteria of SIRS. Patients who were immunocompromised
due to treatment with corticosteroids, receipt of bone marrow or organ transplants, leukopenia
(leukocyte count <1.0 x 109 cells/L) or neutropenia (polymorphonuclear granulocyte count <0.5
x 109 cells/L), a haematologic malignant condition, or AIDS were excluded. Patients who died or
were discharged early (within 12 hours after admission) were also excluded
Patient characteristics and set-
ting
Authors reported information from 52 participants: 14 participants with SIRS without infection
and 38 participants with sepsis. Compared with the SIRS group, the sepsis group tended to be
older (60.0 versus 44.0 years) and comprised more males (86.8% versus 50.0%). The sepsis group
had higher APACHE II (20.0 versus 12.0), SOFA (8.0 versus 6.0), and SAPS II (39.5 versus 27.5)
scores than the SIRS group. Participants with sepsis were hospitalized for a longer time (8.0 versus
3.0 days) and required the use of mechanical ventilation for a longer period (5.5 versus 0.3 days)
. In the sepsis group, bacterial infection was found in 23 participants (60.5%); fungal infection in
2 participants (5.3%); and the remaining 11 (28.9%) participants were infected with both bacteria
and fungus. Among 34 participants infected by bacteria, 14 (26.8%) of them were infected with
Bacillus and 20 (52.6%) were infected with cocci.
Index tests Within 12 hours after admission, 10 mL of whole heparinized blood was drawn via an arterial line
for biomarker measurements. The blood was put on ice, and plasma was collected by centrifugation
at 4 °C, separated into aliquots and stored at −80 °C until use. IL-6 (EK0410; Boster Biological
Technology) was quantified using ELISA tests
Insufficient information to determine if index test results were interpreted without knowledge of
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the results of the reference standard. However, IL-6 results were probably performed automatically
and then were not affected by additional information
Authors reported optimal cut-off values for accuracy data (not prespecified in methods)
Target condition and reference
standard(s)
Target condition: sepsis
Reference standard: 2 intensivists retrospectively reviewed all medical records pertaining to each
patient and independently classified the diagnosis as SIRS (no infection), sepsis, severe sepsis, or
septic shock at the time of ICU admission, according to established consensus definitions (Bone
1992). Both intensivists were blinded to the plasma measurements
Flow and timing Biomarkers samples were taken within 12 hours after admission. 2 intensivists retrospectively re-
viewed all medical records pertaining to each patient and independently classified the diagnosis as
SIRS (no infection), sepsis, severe sepsis, or septic shock at the time of ICU admission
All participants received the same reference standard.
No participants were excluded from the analysis.
Comparative
Notes Funding: no financial
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
Liu 2005
Study characteristics
Patient sampling Authors enrolled all critically ill patients admitted to the ICU from April 2002 to October 2002.
Diagnosis of SIRS systemic infection, severe systemic infection, and septic shock were based on
diagnostic criteria of the American Association of Chest Physicians and Critical Care Medicine
Consensus Conference. Exclusion criteria included thyroid myeloid cell carcinoma or small cell
lung cancer patients
Patient characteristics and set-
ting
Authors reported information from 57 participants: 30 cases of non-infectious SIRS participants
and 27 cases of systemic infection. The average APACHE II score was 11.5 ± 7.8, mean age was
55.9 ± 21.0, and 70.2% of participants were male. Mean SOFA score was 4.9 ± 4.5. A total of 12
participants died
Index tests Serum samples were collected after 3 hours of blood collection. Serum IL-6 levels were measured
by immunofluorescence assay with a sensitivity of 0.1 ug/L; serum IL-6 levels were measured by
ELISA kit
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Insufficient information to determine if index test results were interpreted without knowledge of
the results of the reference standard. However, IL-6 results were probably performed automatically
and then were not affected by additional information
Authors reported optimal cut-off values for accuracy data (not prespecified in methods)
Target condition and reference
standard(s)
Target condition: sepsis
Reference standard: diagnostic criteria of the American Association of Chest Physicians and Critical
Care Medicine Consensus Conference. No further details provided
Unclear if reference standard results were interpreted without knowledge of the results of the index
test
Flow and timing Unclear time interval between IL-6 and reference standard (high probability that samples and criteria
were collected at the same time, but this is not clearly stated)
All participants received the same reference standard.
No participants were excluded from the analysis.
Comparative
Notes Funding: not stated
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
Llewelyn 2013
Study characteristics
Patient sampling Authors enrolled all admissions to the general ICU (17 beds) and HDU (8 beds) at Brighton and
Sussex Hospitals NHS Trust between August 2010 and January 2011, who had study blood samples
within 6 hours of admission and met 2 or more of the SIRS criteria in the first 24 hours of admission
to ICU. Patients were excluded if they were under 18 years of age or where it was not possible to
obtain patient consent or consultant approval to enrol the participant within 6 hours of admission
Patient characteristics and set-
ting
Between August 2010 and January 2011, 198 participants met 2 or more of the SIRS criteria. In 36
participants it was not possible to determine whether infection was present or not. Of the remaining
participants, 87 participants with SIRS (43.9%) were deemed to have sepsis, while 75 (37.9%) were
deemed not to have infection and were thus classified as having non-infective SIRS
Index tests Blood was collected from participants within 6 hours of their admission to the unit. Samples
were taken into sodium citrate tubes, centrifuged, and plasma was stored at −80 °C until the end
of the study, when all samples were analysed for each marker as a single batch. IL-6 levels were
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measured on a Luminex LX200 using Invitrogen’s Human Inflammatory 5-Plex panel (Invitrogen/
Life Technologies, Darmstadt, Germany) and Millipore filter plates (VWR, Darmstadt, Germany)
as per the manufacturer’s instructions. All biomarker analyses were conducted blind to the clinical
data
Authors reported optimal cut-off values for accuracy data (not prespecified in methods)
Target condition and reference
standard(s)
Target condition: sepsis
Reference standard: the 2001 International Sepsis Definitions Conference definitions of SIRS and
sepsis were used. Sepsis was defined as SIRS plus either proven infection (on the basis of microbio-
logical sampling or radiology) or probable infection (considering the patient’s clinical presentation,
white cell count, CRP, radiology), and non-infective SIRS was defined as SIRS associated with
an established underlying non-infective diagnosis and no reason to suspect any ongoing infection.
Categorization of participants was made independently by 2 members of the study team (ML and
SD) blind to the biomarker results, with any disagreements resolved by discussion
Flow and timing Unclear time interval between IL-6 and reference standard (high probability that samples and criteria
were collected at the same time, but this is not clearly stated)
All participants received the same reference standard.
In 36 participants (18.2%), it was not possible to determine with certainty whether infection was
present or not. This group included 4 participants with pancreatitis
Comparative
Notes Funding: Abbott GmbH & Co. KG, Wiesbaden, Germany
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Did all patients receive a refer-
ence standard?
Yes
Unclear
Mat-Nor 2016
Study characteristics
Patient sampling Authors enrolled consecutive adult participants aged older than 18 years who fulfilled the SIRS
definition. This prospective cohort was conducted over 3 years (from July 2011 to June 2014) in a
12-bed ICU of a major tertiary hospital in Pahang, Malaysia
Patients who had received antimicrobial treatment for more than 24 hours before the first blood
samples for biomarker analysis were taken were excluded from the study. If a participant had more
than 1 ICU admission, only the first episode was included in the study
Patient characteristics and set-
ting
239 consecutive participants diagnosed with SIRS were recruited, of whom 164 (69%) were diag-
nosed with sepsis. Participants with sepsis were more severely ill with significantly higher SAPS II
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and SOFA scores on admission as compared to those with non-infectious SIRS. Most participants
in the sepsis group had respiratory as the primary diagnostic class, whereas most non-infectious
SIRS were classified as trauma
Index tests Daily serum concentrations of IL-6 were measured during the first 3 days. The samples were
centrifuged and stored at−80 °C for later analysis. IL-6 was determined usingQuantikine ELISA kit
from R&D Systems (Minnesota, USA). The assay uses quantitative sandwich enzyme immunoassay
technique and normal values corresponding to less than 9.7 pg/mL
Insufficient information to determine if index test results were interpreted without knowledge of
the results of the reference standard. However, IL-6 results were probably performed automatically
and then were not affected by additional information
Authors reported optimal cut-off values for accuracy data (not prespecified in methods)
Target condition and reference
standard(s)
Target condition: sepsis
Reference standard: ACCP criteria (Bone 1992; Levy 2003). 2 intensive care doctors completed
a validated questionnaire for each participant on day 1 and day 3 to define clinical suspicion of
sepsis. Participants were grouped into sepsis if there was clinical suspicion of infection with or
without positive culture; otherwise, they were grouped into non-infectious SIRS. The treating ICU
physicians were blinded to the IL-6 concentrations when caring for participants
Flow and timing Noparticipants were excluded from the analysis. Samples were taken concurrently with the diagnosis
Unclear time interval between IL-6 and reference standard (high probability that samples and criteria
were collected at the same time, but this is not clearly stated)
All participants received the same reference standard.
No participants were excluded from the analysis.
Comparative
Notes Funding: International Islamic University Malaysia Endowment B research grant
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
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Mat-Nor 2016 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
Meynaar 2011
Study characteristics
Patient sampling Authors enrolled all consecutive participants admitted to the ICU between February 2009 and April
2009 if they were expected to be treated in the ICU for more than 24 hours. Exclusion criteria
included patients who had neither SIRS nor sepsis; if patient had more than 1 ICU episode during
the study period, only the first episode was included in the study
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Meynaar 2011 (Continued)
Patient characteristics and set-
ting
A total of 76 participants were included in the study, 32 with sepsis and 44 with SIRS. Participants
with sepsis had significantly higher illness severity scores on admission as compared to participants
with SIRS. Participants with sepsis were more often ventilated and put on renal replacement therapy
Index tests Blood samples for measuring IL-6 were taken on admission and subsequently at 6 A.M. everymorn-
ing until ICU discharge. IL-6 levels were measured using a solid-phase, enzyme-labelled chemilu-
minescent immunometric assay (IMMULITE 2000; Siemens Healthcare, the Netherlands). A cut-
off level of 50 mg/L is commonly used in clinical practice
Insufficient information to determine if index test results were interpreted without knowledge of
the results of the reference standard. However, IL-6 results were probably performed automatically
and then were not affected by additional information
Unclear if reported optimal cut-off values for accuracy data were prespecified in the methods
Target condition and reference
standard(s)
Target condition: sepsis
Reference standard: signs of SIRS + bacterial infection (Bone 1992). The final diagnosis of sepsis
or SIRS was made at a later stage from participant records and blinded to IL-6 results
Flow and timing IL-6 values were taken during 24 hours of admission. Categorization was made at the later stage
All participants received the same reference standard.
No participants were excluded from the analysis.
Comparative
Notes Funding: IL-6 kits were supplied free by Siemens Healthcare
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Meynaar 2011 (Continued)
If a threshold was used, was it
pre-specified?
Unclear
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
Moscovitz 1994
Study characteristics
Patient sampling Authors enrolled participants admitted through the emergency department of the Hospital of the
University of Pennsylvania. Patients were enrolled if they had: a) the presumptive diagnosis of
bacteraemia as defined by the decision of the emergency physician to perform blood cultures; and
b) findings of infection. Patients were excluded if they were known to have neoplastic disease or
AIDS, if they were pregnant, or if they were currently taking immunosuppressive therapy, NSAID,
or antibiotics
Unclear if participants were enrolled in a consecutive or random fashion
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Moscovitz 1994 (Continued)
Patient characteristics and set-
ting
100 participants were enrolled in the study, 63 females and 37 males, with a median age of 51 years.
18 participants were bacteraemic at entry. A total of 32 participants who were not bacteraemic had
a positive bacterial culture at 1 or more culture sites
Index tests Blood samples for cytokine determinations were obtained from participants in the emergency de-
partment before the administration of antibiotics. IL-6 concentrations were measured using ELISA
kits (Genzyme, Cambridge, MA, USA). Plasma samples for IL-6 determinations were diluted 3-
fold before assay with diluent (Genzyme). The limits of detection were 160 pg/mL for IL-6
Insufficient information to determine if index test results were interpreted without knowledge of
the results of the reference standard. However, IL-6 results were probably performed automatically
and then were not affected by additional information
Authors reported optimal cut-off values for accuracy data (not prespecified in methods)
Target condition and reference
standard(s)
Target condition: bacteraemia
Reference standard: SIRS criteria + microbiological evidence of local infection
Unclear if reference standard results were interpreted without knowledge of the results of the index
test
Flow and timing Unclear time interval between IL-6 and reference standard (high probability that samples were
collected at the same time, but this is not clearly stated)
All participants received the same reference standard.
Unclear data (there were apparently no data for IL-6 for 7 participants). No further data available
Comparative
Notes Funding: Ethel B. Foerderer Fund for Excellence of the Children’s Hospital of Philadelphia
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Yes
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Moscovitz 1994 (Continued)
dard?
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Did all patients receive a refer-
ence standard?
Yes
Unclear
Ramirez 2009
Study characteristics
Patient sampling Authors included all participants expected to remain in mechanical ventilation for more than 48
hours and admitted to a 21-bed medical ICU in an 18-month period, without any active infection.
Patients developing nosocomial infection other than VAP during hospitalization were excluded on
diagnosis of these infections
Patient characteristics and set-
ting
44 participants receivingmechanical ventilationwere screened during the study period and included.
20 participants were suspected of having VAP throughout their ICU stay. Microbiological analysis
of bronchoalveolar lavage confirmed the presence of VAP in 9 cases; the causative micro-organisms
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Ramirez 2009 (Continued)
were Staphylococcus aureus (3 cases), Acinetobacter baumannii (3 cases), Klebsiella pneumoniae (2
cases), and Streptococcus pneumoniae (1 case). The non-microbiologically confirmed cases were not
considered as having VAP
Index tests Authors determined IL-6 at the day of study inclusion and every 96 hours. The blood samples
taken for determination of inflammatory markers were centrifuged (1500 rpm, 10 min), and the
supernatant was frozen at −80 °C. The determination of IL-6 was performed with a commercial
enzimoimmunoassay technique (BioSource, Nivelles, Belgium)
Insufficient information to determine if index test results were interpreted without knowledge of
the results of the reference standard. However, IL-6 results were probably performed automatically
and then were not affected by additional information
Authors reported optimal cut-off values for accuracy data (not prespecified in methods)
Target condition and reference
standard(s)
Target condition: ventilator-associated pneumonia
Reference standard: VAP was suspected if participants met either: a) clinical criteria (new or progres-
sive radiologic pulmonary infiltrate together with 2 of the following: temperature >38 °C, leukocy-
tosis >12,000/mm3 or leukopenia <4000/mm3 , or purulent respiratory secretions); or b) a simpli-
fied Clinical Pulmonary Infection Score ≥5 points. VAP was confirmed if the quantitative culture
of BAL yielded 104 colony-forming units per millilitre
Unclear if reference standard results were interpreted without knowledge of the results of the index
test
Flow and timing Cytokines values were available at the day of VAP suspicion.
All participants received the same reference standard.
No participants were excluded from the analysis.
Comparative
Notes Funding: CibeRes and IDIBAPS
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test All tests
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Ramirez 2009 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
Sakr 2008
Study characteristics
Patient sampling Authors included all consecutive participants admitted to a surgical ICU between January 2001
and November 2001 with an estimated ICU length of stay of more than 48 hours. Exclusion
criteria included patients younger than 18 years of age, patients with advancedmalignancies or other
conditions with shortened life expectancy (4 weeks), pregnancy, previous inclusion in the study, and
patients for whom decisions to withhold or withdraw life-sustaining treatments were established
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Sakr 2008 (Continued)
within the first 24 hours of ICU admission
Patient characteristics and set-
ting
327 participants were included (207 males; mean age 63 years). 74 postoperative participants were
referred from other facilities and did not undergo any surgical procedure in the 48 hours preceding
ICU admission because of respiratory failure (n = 24), severe sepsis (n = 9), deterioration in the
level of consciousness (n = 14), trauma (n = 6), successful cardiopulmonary resuscitation (n = 4),
acute renal failure (n = 5), congestive heart failure or myocardial ischaemia (n = 5), gastrointestinal
bleeding (n = 4), seizures (n = 2), and arrhythmia (n = 1). The median ICU length of stay was 6
days (25% to 75% IQR: 4 to 13 days), and the overall ICU mortality rate was 15% (n = 49). The
SAPS II score varied considerably among the subgroups
Index tests Blood samples were collected daily during the first week after admission to the ICU. IL-6 con-
centrations were measured with a commercially available immunoassay system (Immulite; DPC
Biermann). The values of markers recorded on the first day of the diagnosis of sepsis syndromes or
those recorded on the ICU admission day in patients without sepsis were used for this analysis
Insufficient information to determine if index test results were interpreted without knowledge of
the results of the reference standard. However, IL-6 results were probably performed automatically
and then were not affected by additional information
Authors reported optimal cut-off values for accuracy data (not prespecified in methods)
Target condition and reference
standard(s)
Target condition: sepsis
Reference standard: sepsis, severe sepsis, and septic shock were defined according to the ACCP/
SCCM consensus conference criteria by the attending senior intensivist. Participants were catego-
rized according to the worst grade of sepsis syndrome in the ICU
Unclear if reference standard results were interpreted without knowledge of the results of the index
test
Flow and timing In this study, values of markers recorded on the first day of the diagnosis of sepsis syndromes or
those recorded on the ICU admission day in participants without sepsis were used
All participants received the same reference standard.
No participants were excluded from the analysis.
Comparative
Notes Funding: Thuringian Ministry of Science and unrestricted grant of DPC Biermann GmbH, Bad
Nauheim, Germany
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Sakr 2008 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
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Tromp 2012
Study characteristics
Patient sampling Authors enrolled participants in a prospective manner from an ED in the Netherlands during an 8-
month period. Inclusion criteria were: patients (16 years old) visiting the ED because of a suspected
infection, who had at least 2 of the following clinical signs of sepsis: temperature > 38.3 °C or <
36 °C, heart rate > 90/min, respiratory rate > 20/min, chills, altered mental status, systolic blood
pressure < 90 mmHg, MAP < 65 mmHg, and hyperglycaemia in the absence of diabetes mellitus.
Exclusion criteria were not clearly stated
Patient characteristics and set-
ting
Authors reported information from 342 participants, of whom 55 (16%) had proven bacteraemia
(positive blood culture). The most common causative agents were Escherichia coli (29%) and Strep-
tococcus pneumoniae (23%). 37 participants with proven bacteraemia received antibiotics in the ED
(67%). There was no significant difference in the administration of antibiotics between the patient
group that was found to have positive blood cultures and the patient group with negative blood
cultures
Index tests An additional blood sample was taken for measurement of IL-6. Blood was collected in 3-millilitre
lithium heparin-coated tubes. Plasma was obtained by centrifugation of the blood at 4 °C and 2200
g for 10 min. Plasma for the measurement of IL-6 was frozen at −80 °C. IL-6 was measured using
the Immulite 2500 (Siemens Healthcare Diagnostics, Deerfield, IL, USA) with a detection limit of
2.00 pg/mL
Insufficient information to determine if index test results were interpreted without knowledge of
the results of the reference standard. However, IL-6 results were probably performed automatically
and then were not affected by additional information
Authors reported optimal cut-off values for accuracy data (not prespecified in methods)
Target condition and reference
standard(s)
Target condition: bacteraemia
Reference standard: bacteraemia was defined as growth of any pathogen in 1 or both blood cul-
ture sets. The isolation of coagulase-negative staphylococci was considered as contamination and
therefore not defined as bacteraemia. The final confirmed diagnosis at discharge was based on a
combination of clinical signs and symptoms of sepsis, the presence/absence of an infiltrate on chest
X-ray, laboratory parameters, and culture results (e.g. blood, urine, sputum, and wound) obtained
during the first 24 h following ED admission. No further details provided
Unclear if reference standard results were interpreted without knowledge of the results of the index
test
Flow and timing Samples were taken concurrently with suspicion of sepsis.
All participants received the same reference standard.
Unclear information for 52 participants not included in final analysis (394 participants admitted
to ED, 342 participants analysed)
Comparative
Notes Funding: no source of funding received. Kits for PCT, IL-6, and LBP donated by Brahms and
Siemens
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
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Tromp 2012 (Continued)
Did all patients receive a refer-
ence standard?
Yes
Unclear
Tsalik 2012
Study characteristics
Patient sampling Authors included information from 2 sources: the Community Acquired Pneumonia and Sepsis
Outcome Diagnostics study (CAPSOD; ClinicalTrials.gov NCT00258869) and the Duke Febrile
Illness Cohort (DFIC; Grant/Cooperative Agreement Number U38/CCU423095)
Eligible participants were identified in the Duke University Medical Center ED (annual census 70,
000) and the Durham VAMC (annual census 40,000) over 2 periods: July 2003 to December 2003
and December 2006 to December 2007. Inclusion and exclusion criteria were the same for both
studies and consist of the following: known or suspected infection at the time of screening with 2 or
more SIRS criteria. Patients were excluded if they were < 18 years old, had an imminently terminal
comorbid condition, had HIV/AIDS with CD4 count < 50 cells/mL, or were receiving antibiotics
for an unrelated condition
Patient characteristics and set-
ting
Authors reported information from336 participants with suspected sepsis in the ED. 89 participants
(26.5%) had non-infectious aetiologies at the time of initial presentation. Of the remaining 247
participants, 202 (81.8%) had uncomplicated sepsis, 28 (11.3%) had severe sepsis, and 17 (6.9%)
had septic shock. Staphylococcus aureus (n = 36) and Escherichia coli (n = 24) together accounted
for 53.1% of identified aetiologies. Lung, urinary tract, and skin together accounted for 60.6% of
identified sites. Blood cultures were true-positive in 55 of 259 (21.2%) participants
Index tests Samples for biomarker determination were frozen after their collection. They were later thawed at
room temperature, gently mixed, and analysed within 8 hours. Measurements of IL-6 are unaffected
by a single freeze-thaw cycle (24 to 26). IL-6 measured on a Roche Elecsys 2010 analyser (Roche
Diagnostics, Laval, Canada) by electrochemiluminescent immunoassay
Insufficient information to determine if index test results were interpreted without knowledge of
the results of the reference standard. However, IL-6 results were probably performed automatically
and then were not affected by additional information
Authors reported 3 optimal cut-off values for accuracy data (not prespecified in methods)
Target condition and reference
standard(s)
Target condition: infection/sepsis
Reference standard: 1 of 2 study physicians with board certification in emergency medicine or in-
ternal medicine reviewed study data and the medical record excluding biomarker data. Determina-
tions were made regarding likelihood of infection, site of infection, and causative organisms (SIRS
criteria). Authors modified a previously published scale to define the likelihood of infection
Flow and timing Unclear time interval between IL-6 and reference standard (high probability that samples and criteria
were collected at the same time, but this is not clearly stated)
All participants received the same reference standard.
No participants were excluded from the analysis.
Comparative
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Notes Funding: NIH grant, National Institute of Allergy and Infectious Diseases grant, Roche Molecular
Sciences grant
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
High Unclear
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Tsalik 2012 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
Tsantes 2013
Study characteristics
Patient sampling Authors reported information form 100 patients with ALI/ARDS treated in the mixed medical/
surgical ICU of the Attikon University Hospital of Athens during a 3-year period (June 2007 to
June 2010). Participants were classified as severe sepsis or septic shock, or both according to ACCP/
SCCM criteria. Participants with ARDS who fulfilled sepsis criteria and had positive cultures and/
or compatible history/physical examination/laboratory were labelled as suffering from septic ARDS,
while those with negative cultures, no other evidence of infection, and a clearly associated with the
development of ARDS inciting factor were registered as having non-septic ARDS
Unclear if participants were enrolled in a consecutive or random manner
Exclusion criteria not clearly stated.
Patient characteristics and set-
ting
100 participants (79 ARDS and 21 ALI) were included, among which 58% were suffering from
septic ALI/ARDS. 78 participants were classified as medical and 22 as surgical. The admission
diagnosis can be grouped as follows: 57 participants with respiratory failure, 19 with septic shock,
11 with multiple trauma, 7 requiring postoperative monitoring and care, and 6 with altered mental
status. The median (IQR) time of ARDS diagnosis following admission was 6 (2 to 12) days.
The sites of infection in septic ARDS participants (n = 58) were determined as follows: lung 28,
bloodstream 18, skin-soft tissue 2, central nervous system 2, abdomen 7, and urinary tract (acute
pyelonephritis) 1, while the following causes of non-septic ARDS (n = 42) were identified: aspiration
21, trauma 11, multiple transfusions 3, pancreatitis 3, and drug overdose 4
Index tests Blood samples were drawn using EDTA blood collection tubes on study enrolment and prior to
BAL procedure, and were immediately centrifuged at 1500 g for 30 min at 4 °C (or placed on ice
and centrifuged within 1 hour). Plasma was snap-frozen in small portions and stored at −80 °C
until the assays were performed. IL-6 levels were assessed by the Elecsys IL-6 immunoassay. The
measuring IL-6 detection range was between 1.5 and 5000 pg/mL
Insufficient information to determine if index test results were interpreted without knowledge of
the results of the reference standard. However, IL-6 results were probably performed automatically
and then were not affected by additional information
Authors reported optimal cut-off values for accuracy data (not prespecified in methods)
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Target condition and reference
standard(s)
Target condition: sepsis
Reference standard: ACCP/SCCM criteria. No details about administration were provided
Unclear if reference standard results were interpreted without knowledge of the results of the index
test
Flow and timing Unclear time interval between IL-6 and reference standard (high probability that samples and criteria
were collected at the same time, but this is not clearly stated)
All participants received the same reference standard.
No participants were excluded from the analysis.
Comparative
Notes Funding: not stated
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Unclear
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
Zhao 2014
Study characteristics
Patient sampling Authors enrolled in a prospective fashion SIRS participants treated in the emergency department
of Beijing Chaoyang Hospital from March 2010 to March 2013. Inclusion criteria included age ≥
18 years; non-surgical trauma participants; survival time in emergency rescue room ≥ 24 hours.
Exclusion criteria: patients with haematological or immunodeficiency diseases; patients who are
using anticoagulants or hormones
Patient characteristics and set-
ting
Authors reported information from 652 cases, 357 males and 295 females; ages ranged from 18 to
96 years; 452 cases have infection and 200 cases non-septic conditions. Severe sepsis was diagnosed
in 160 cases, and 30 cases have septic shock
Index tests Blood samples taken at arrival to ED. Authors used ELISA for IL-6 detection (RapidBio kit)
Insufficient information to determine if index test results were interpreted without knowledge of
the results of the reference standard. However, IL-6 results were probably performed automatically
and then were not affected by additional information
Authors reported optimal cut-off values for accuracy data (not prespecified in methods)
Target condition and reference
standard(s)
Target condition: sepsis
Reference standard: the definition of SIRS, sepsis, severe sepsis, and septic shock was consistent
with the diagnostic criteria established at the 2001 Washington International Septic Deficiency
Conference. All participants were divided into sepsis group and non-sepsis group according to the
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diagnosis of sepsis. No further details available
Unclear if reference standard results were interpreted without knowledge of the results of the index
test
Flow and timing Unclear time interval between IL-6 and reference standard (high probability that samples and criteria
were collected at the same time, but this is not clearly stated)
All participants received the same reference standard.
No participants were excluded from the analysis.
Comparative
Notes Funding: not stated
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Zhao 2014 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Low
ACCP: AmericanCollege ofChest Physicians;ALI: acute lung injury;APACHE score: Acute Physiology andChronicHealth Evaluation
score; ARDS: acute respiratory distress syndrome; BAL: bronchoalveolar lavage; CAPSOD: Community Acquired Pneumonia and
Sepsis OutcomeDiagnostics study;CD4: quadruple differentiation 4;CRP: C-reactive Protein;EASIA: enzyme amplified sensitivity
immunoassay; ESICM: European Society of Intensive Medicine; ED: emergency department ; EDTA: ethylenediaminetetraacetic
acid;ELISA: enzyme-linked immunosorbent assay; g: unit for centrifugation steps;HDU: high-dependency unit; ICU: intensive care
unit; IL-6: interleukin-6; IL-8: interleukin-8; IQR: interquartile range; LBP: lipopolysaccharide binding protein; MAP: mitogen-
activated protein;NSAID:Non-steroidal Anti-inflammatoryDrugs;NHS: UKNationalHealth Service;NIH: USNational Institutes
of Health; PaCO2:Partial pressure of carbon dioxide in arterial blood; PCT: procalcitonin; rpm: revolutions per minute; SAPS:
Simplified Acute Physiology Score; SCCM: Society of Critical Care Medicine; SIRS: systemic inflammatory response syndrome;
SOFA: Sequential Organ Failure Assessment; VAMC: Veterans Affairs Medical Center; VAP: ventilator-associated pneumonia.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aikawa 2005 No critically ill patients involved (unclear source).
Angeletti 2015 Case-control study
Aznar-Oroval 2010 No critically ill patients enrolled.
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BalcI 2003 Analysis was based on events of sepsis instead of patients with sepsis
Behnes 2014 No sensitivity/specificity data for IL-6
Byl 1997 All patients with sepsis criteria at admission
Carlyn 2015 AUROC analysis was used to evaluate the usefulness of the detectable biomarkers in determining the
severity of the septic state
Chalupa 2011 No critically ill patients enrolled.
Chen 2018 No sensitivity/specificity data for IL-6
de Bont 1999 Insufficient data about accuracy of IL-6; children included in the sample (no subgroup analysis)
de Mendonca-Filho 2005 Comparison focused on positive versus negative cultures; all patients with sepsis
Durila 2012 Prediction of sepsis during postoperative follow-up
Endo 2008 No sensitivity/specificity data for IL-6
Feng 2016 Case-control study
Fink-Neuboeck 2016 Prediction of postoperative SIRS
Gaini 2006 Patients from department of internal medicine (no critically ill patients)
Gaini 2007 Patients from department of internal medicine (no critically ill patients)
Giamarellos 2008 No sensitivity/specificity data for IL-6
Gille-Johnson 2012 Not focused on diagnosis of sepsis (prediction of infections requiring antibiotics)
Groeneveld 2001 Prediction of bloodstream infection at 7 days after inclusion
Grover 2014 No sensitivity/specificity data for IL-6
Gurlich 1998 No sensitivity/specificity data for IL-6
Hamed 2017 Case-control study
Hoenigl 2014 No sensitivity/specificity data for IL-6
Huang 2016 No sensitivity/specificity data for IL-6
Iapichino 2010 Analysis based on patient days, not on participants.
80Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Kweon 2014 Case-control study
Lin 2015 Prediction of sepsis during hospitalization
Linder 2009 Diagnosis of severity of sepsis (septic shock)
Lukaszewski 2008 Prediction of sepsis
Mandi 2000 No critically ill patients
Mardi 2010 Case-control study
Marie 2018 No accuracy data for IL-6
Maruna 2002 No sensitivity/specificity data for IL-6
Maruna 2011 Prediction of infection (1 to 3 days postoperative)
Mickiewicz 2015 No sensitivity/specificity data for IL-6
Mokart 2005 Prediction of postoperative sepsis after major surgical procedures
Muller 2000 Unclear data about groups compared
Nierhaus 2012 Unclear data about groups compared
Parenica 2014 Diagnosis of cardiogenic shock
Pauly 2016 No sensitivity/specificity data for IL-6
Prat 2008 No sensitivity/specificity data for IL-6
Qu 2015 No critically ill patients enrolled (admissions from infectious disease department)
Rau 2010 Diagnosis of rheumatological disease
Ravishankaran 2011 Prediction of sepsis after surgery
Reichsoellner 2014 Case-control study
Rettig 2016 Insufficient report of IL-6 data about accuracy (composite endpoint = complications)
Sander 2006 Prediction of sepsis after surgery
Schefold 2008 Analysis based on serum samples instead of patients.
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(Continued)
Shozushima 2011 No sensitivity/specificity data for IL-6
Takahashi 2014 IL-6 measured in cerebrospinal fluid.
Takahashi 2016 Case-control study
Talebi-Taher 2014 Case-control study
Tasabehji 2008 No sensitivity/specificity data for IL-6
Uusitalo-Seppala 2011 No sensitivity/specificity data for IL-6
Uusitalo-Seppälä 2012 No sensitivity/specificity data for IL-6
Vanska 2012 Prediction of complicated course in febrile neutropenia
von Dossow 2005 Progression to septic shock
von Lilienfeld-Toal 2004 Febrile episodes instead of patients
Wang 2010 Case-control study
Weiss 2006 All patients with severe sepsis at admission
Wutzler 2009 No sensitivity/specificity data for IL-6
Yang 2016 Predictionof sepsis (infectionduring ICU stay; blood samples takenwithin 12 hours after ICUadmission)
Yousef 2010 No sensitivity/specificity data for IL-6
Zhao 2018 Case-control study
AUROC: area under the receiver operating characteristic curve; ICU: intensive care unit; IL-6: interleukin-6; SIRS: systemic inflam-
matory response syndrome.
Characteristics of studies awaiting classification [ordered by study ID]
Balci 2017
Study characteristics
Patient sampling Not stated
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Balci 2017 (Continued)
Patient characteristics and set-
ting
ICU patients with suspected infection admitted to the Health Sciences University, Kocaeli Derince
Training Hospital’s ICU
Index tests Heparin-binding protein, PCT, TNF-alpha, IL-6, and C-reactive protein levels
Target condition and reference
standard(s)
Sepsis
Flow and timing Blood samples were taken on the 1st and 2nd day of hospitalization, and the 7th day, on day of
discharge, or on the day of death
Comparative Not stated
Notes Conference proceeding.
Objective (quote): “The present study was conducted to determine the heparin-binding protein,
procalcitonin level at early diagnosis in patients with sepsis, in comparison with C-reactive protein,
IL-6 and TNF-alfa.” Page 1. Authors state that this study is ongoing
Blouin 2018
Study characteristics
Patient sampling Not stated
Patient characteristics and set-
ting
Cancer patients admitted with sepsis to the Urgent Care Center and ICU
Index tests TNF-alpha, IL-10, IL-1b, and IL-6
Target condition and reference
standard(s)
Sepsis
Flow and timing 2880 serum PCT results from 1944 patients were evaluated from December 2015 to June 2017
Comparative Not stated
Notes Conference proceeding
Objective (quote): “We aimed to evaluate the performance of PCT and 4 citokines (TNF alpha,
IL-10, IL-1b and IL-6) for the diagnosis of bacterial bloodstream infections in critically ill cancer
patients.” Page 698
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Cate 2013
Study characteristics
Patient sampling Not stated
Patient characteristics and set-
ting
Emergency department patients with SIRS and/or another sepsis risk factor (hypotension (SBP <
100), altered mental status, immunodeficiency, advanced age, or hyperglycaemia without diabetes)
who were admitted to the medical ICU
Index tests IL-6
Target condition and reference
standard(s)
Sepsis
Flow and timing Residual plasma specimens collected at ED admission were utilized
Comparative Not stated
Notes Conference proceeding
Objective (quote): “to identify sepsis prediction models for ED patients with systemic inflammatory
response syndrome (SIRS) and/or other sepsis risk factors” Page A197
Cebreiros-Lopez 2017
Study characteristics
Patient sampling 50 patients presenting at the ED with suspected sepsis were included
Patient characteristics and set-
ting
Blood samples were collected at first medical evaluation, and IL-6 was analysed. After diagnosis,
the patients were divided into 2 groups: group A (non-infectious aetiology, localized infection, or
SIRS) and group B (sepsis, severe sepsis, or septic shock)
Index tests IL-6
Target condition and reference
standard(s)
Sepsis
Flow and timing Not stated
Comparative Not stated
Notes Conference proceeding
Objective (quote): “the aim of this study was to investigate the diagnostic value of IL6 compared
to PCT” Page S147
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Das 2012
Study characteristics
Patient sampling Not stated
Patient characteristics and set-
ting
3 patient groups, age > 18 years: group 1 (n = 41), proven infection; group 2 (n = 29), clinically
suspected infection but negative culture; group 3 (n = 29), patients with SIRS
Index tests IL-6
Target condition and reference
standard(s)
Sepsis (microbiological cultures)
Flow and timing Blood was collected at the time of admission for microbiological culture and estimation of IL-6
Comparative Not stated
Notes Conference proceeding
Objective (quote): “the aim of this study was to evaluate the diagnostic role of PCT and IL-6 in
differentiating sepsis (both culture positive and culture negative) from SIRS” Page 1
Fukui 2012
Study characteristics
Patient sampling 18 patients operated at Kochi Health Sciences Center between April 2010 and March 2011
Patient characteristics and set-
ting
9 patients with acute abdomen; 5 with oesophageal cancer; 2 with cerebral bleeding; and 1 each
with Fournier’s gangrene and trauma
Index tests IL-6
Target condition and reference
standard(s)
Sepsis. Sepsis was diagnosed according to ACCP/SCCM criteria
Flow and timing Not stated
Comparative Not stated
Notes Conference proceeding
Objective (quote): “in this study,we evaluated the specificity, clinical effectiveness of soluble sCD14st
in patients with surgical sepsis” Page S2
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Hakobyan 2012
Study characteristics
Patient sampling 1589 patients observed between 2004 and 2011
Patient characteristics and set-
ting
63 (16.6%) patients (76.3% (n = 200) male and 23.7% (n = 63) female) had sepsis. Average age was
16 to 84 years (43.8 ± 17.1). Days of hospitalization were 18.1 ± 18.8 (2 to 116 days); mortality
33.8%; consciousness by Glasgow Coma Scale 11.8 ± 7.6 points
Index tests Cytokines (unclear if IL-6 was included)
Target condition and reference
standard(s)
Sepsis
Flow and timing Not stated
Comparative Not stated
Notes Conference proceeding
Objective (quote): “the aim of study was to analyse informativity of current markers of sepsis
(procalcitonin, glucose, C-reactive protein, microbiological methods). The purpose was to improve
current diagnosing of sepsis” Page Sii85
Kawano 2016
Study characteristics
Patient sampling Single-centre retrospective cohort study of patients who were admitted to the emergency ICU of
the Fukuoka University Hospital, Japan, from May 2013 to April 2015
Patient characteristics and set-
ting
232 patients were enrolled into this analysis.
Index tests IL-6
Target condition and reference
standard(s)
Sepsis and septic shock
Flow and timing Not stated
Comparative Not stated
Notes Conference proceeding
Objective (quote): “the purpose of this studywas to evaluate the clinical usefulness of sepsis biomark-
ers according to the new definitions of sepsis” Page 412
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Kriplani 2017
Study characteristics
Patient sampling Not stated
Patient characteristics and set-
ting
100 patients admitted to the Breach Candy Hospital Trust
Index tests IL-6 and procalcitonin
Target condition and reference
standard(s)
Sepsis
Flow and timing Not stated
Comparative Not stated
Notes Conference proceeding
Objective (quote): “to identify alterations in haematological parameters like immature granulocytes,
eosinopenia, immature platelet fraction, changes in morphology. 2. To correlate the haematological
parameters with clinical findings and biomarkers of sepsis like IL-6 and procalcitonin. 3. To establish
haematological parameters as reliable initial markers of infections bacterial and viral” Page S67
Mendu 2015
Study characteristics
Patient sampling Observational quality improvement study evaluating 25 patients who were admitted to the ICU
with suspected severe sepsis or septic shock over a 6-month period
Patient characteristics and set-
ting
Setting: adult oncology medical-surgical ICU at a tertiary cancer centre. Participants: 24 patients
(10 with suspected severe sepsis or septic shock and 14 control participants)
Index tests IL-6
Target condition and reference
standard(s)
Sepsis
Flow and timing IL-6 levels were measured within 24 hours (Day 1) of ICU admission. The samples were batched,
and the cytokine results were not available for clinical use
Comparative Not stated
Notes Conference proceeding
Objective (quote): “our objective was to evaluate the diagnostic and prognostic value of procalcitonin
(PCT) and 5 select cytokines (TNF-α, IL-1β, IL-6, IL-8, interferon-gamma (IFN-γ ) in cancer
patients admitted to the ICU with suspected severe sepsis and septic shock” Page S11
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Mikaszewska-Sokolewicz 2010
Study characteristics
Patient sampling Not stated
Patient characteristics and set-
ting
92 adult patients (45 males and 47 females aged 18 to 93 years) with symptoms of inflammatory
reaction and multiple organ failure, admitted to general ICU
Index tests IL-6
Target condition and reference
standard(s)
Sepsis
Flow and timing Not stated
Comparative Not stated
Notes Conference proceeding
Objective (quote): “clinical biomarkers of sepsis can be easily detected by bed site diagnostic tools.
This process can add useful message to decision making process. The study was performed to
determine if additional bed site tests can accelerate implementation of septic bundles and influence
duration of treatment in the ICU.” Page S314
Murai 2012
Study characteristics
Patient sampling Observational cohort study in critically ill patients in the ICU of a tertiary care hospital
Patient characteristics and set-
ting
49 participants were enrolled.
Index tests IL-6
Target condition and reference
standard(s)
Sepsis
Flow and timing Not stated
Comparative Not stated
Notes Conference proceeding
Objective (quote): “we performed an observational cohort study in critically ill patients in the ICU
of a tertiary care hospital. We investigated the correlation between endotoxin activity levels and
blood concentration of endotoxin measured by the chromogenic limulus amoebocyte lysate (LAL)
assay, causative microorganism identified in laboratory culture, procalcitonin (PCT), soluble CD14
subtype (named presepsin), IL-6, antithrombin, protein C, thrombomodulin, lactate, disseminated
intravascular coagulation scores in both the JapaneseMinistry ofHealth andWelfare and the Japanese
Association for Acute Medicine, and severity of illness at ICU admission.” Page S12
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Nakadai 2013
Study characteristics
Patient sampling Not stated
Patient characteristics and set-
ting
207 patients with SIRS
Index tests IL-6
Target condition and reference
standard(s)
Sepsis; blood cultures
Flow and timing Not stated
Comparative Not stated
Notes Conference proceeding
Objective (quote): “to evaluate the clinical application of measuring procalcitonin (PCT) level for
diagnosis of bacterial sepsis in patients with and without systemic inflammatory response syndrome
(SIRS), we studied the relationship between blood culture (BC) and serum PCT level in clinical 207
cases. In addition, we evaluated the time courses of PCT and other inflammatory markers: tumour
necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), E-selectin, white blood cell count and C-
reactive protein (CRP) in 5 bacterial septic patients with SIRS” Page 781
Nishida 2012
Study characteristics
Patient sampling Single-centre, prospective, observational study. Patients who had 1 or more SIRS criteria were
included. 84 patients were enrolled from June 2010 to June 2011
Patient characteristics and set-
ting
Not stated
Index tests IL-6
Target condition and reference
standard(s)
Sepsis
Flow and timing The blood samples for measuring the markers were collected, and the severity of sepsis was evaluated
at the time of admission and every other day for a week
Comparative Not stated
Notes Conference proceeding
Objective (quote): “the aims of this study were to investigate the most useful biomarkers which are
serum levels of soluble CD14 subtype (sCD14-ST) named presepsin, procalcitonin (PCT), IL-6,
and C-reactive protein (CRP) as markers for early diagnosis of sepsis” Page S11
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Oberhoffer 2000
Study characteristics
Patient sampling Prospective consecutive case series
Patient characteristics and set-
ting
Setting: surgical ICU of a university hospital. 243 patients experiencing ICU stays of longer than
48 hours categorized for sepsis were included
Index tests IL-6
Target condition and reference
standard(s)
Sepsis; ACCP/SCCM Consensus Conference criteria
Flow and timing Not stated
Comparative Not stated
Notes Conference proceeding
Objective (quote): “to determine the correlations and predictive strength of surrogate markers (body
temperature, leukocyte count, C-reactive protein (CRP) and procalcitonin (PCT)) with elevated
levels of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in septic patients on
randomly chosen days” Page S11
Pyle 2011
Study characteristics
Patient sampling Not stated
Patient characteristics and set-
ting
63 leftover plasma samples collected from ICU patients on the first day they had SIRS (identified
though an automated electronic medical record scan) were included. Of these, 26 had culture-
confirmed sepsis and 37 had no bacterial infection within ±3 days of specimen collection
Index tests IL-6
Target condition and reference
standard(s)
Sepsis
Flow and timing Not stated
Comparative Not stated
Notes Conference proceeding
Objective (quote): “our objective was to identify a panel of biomarkers that detects sepsis in ICU
patients with SIRS” Page 468
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Rotar 2017
Study characteristics
Patient sampling Not stated
Patient characteristics and set-
ting
70 patients with severe acute necrotizing pancreatitis in a single intensive care department of regional
hospital were assessed
Index tests Levels of presepsin as well as procalcitonin, IL-6, and C-reactive protein at admission
Target condition and reference
standard(s)
Infection
Flow and timing Not stated
Comparative Not stated
Notes Conference proceeding
Objective (quote): “to establish utility of presepsin (PSP) for diagnosis of local and systemic infection
during ANP” Page S57
Tong 2014
Study characteristics
Patient sampling Retrospective clinical study
Patient characteristics and set-
ting
131 patients in the surgical ICU who had SIRS but not sepsis from March 2012 to March 2013
Index tests IL-6
Target condition and reference
standard(s)
Sepsis
Flow and timing Not stated
Comparative Not stated
Notes Conference proceeding
Objective (quote): “this study was designed to analyse and compare the ability of 8 biomarkers with
their accuracy in an early prediction of sepsis” Page S153
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Uchimido 2017
Study characteristics
Patient sampling Prospective, observational study of a convenience sample of adult ED patients with suspected
infection and non-infected ED controls, conducted from September 2009 to April 2014
Patient characteristics and set-
ting
Not stated
Index tests IL-6
Target condition and reference
standard(s)
Sepsis
Flow and timing Not stated
Comparative Not stated
Notes Conference proceeding
Objective (quote): “to define the association of circulating endocan levels with inflammation, en-
dothelial cell signalling, sepsis severity, and organ dysfunction (SOFA score) in Emergency Depart-
ment (ED) patients with sepsis” Page S28
Woo 2015
Study characteristics
Patient sampling Retrospective cohort study conducted from January 2013 to December 2013
Patient characteristics and set-
ting
122 patients with SIRS, 55 of which were classified as the older age group (> 65 years). 33 (60%)
patients in the older group and 40 (59.7%) patients in the other group had sepsis
Index tests IL-6
Target condition and reference
standard(s)
Sepsis
Flow and timing Not stated
Comparative Not stated
Notes Conference proceeding
Objective (quote): “we assessed the diagnostic value of PCT and IL-6 in older patients and other
patients with SIRS and sepsis in the ED” Page S21
ACCP: American College of Chest Physicians; ED: emergency department; ICU: intensive care unit; IL-1b: interleukin-1b; IL-6:
interleukin-6; IL-10: interleukin-10; PCT: procalcitonin; SBP: systolic blood pressure; SCCM: Society of Critical Care Medicine;
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SIRS: systemic inflammatory response syndrome; SOFA: Sequential Organ Failure Assessment; TNF-alpha: tumour necrosis factor
alpha
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Plasma interleukin-6
concentrations
21 3650
Test 1. Plasma interleukin-6 concentrations.
Review: Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adults
Test: 1 Plasma interleukin-6 concentrations
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Aalto 2004 8 10 3 69 0.73 [ 0.39, 0.94 ] 0.87 [ 0.78, 0.94 ]
Anand 2015 46 5 26 41 0.64 [ 0.52, 0.75 ] 0.89 [ 0.76, 0.96 ]
Du 2003 17 8 3 23 0.85 [ 0.62, 0.97 ] 0.74 [ 0.55, 0.88 ]
Endo 2012 97 31 18 39 0.84 [ 0.76, 0.90 ] 0.56 [ 0.43, 0.68 ]
Fu 2013 58 80 37 122 0.61 [ 0.51, 0.71 ] 0.60 [ 0.53, 0.67 ]
Gomez 2010 66 8 33 20 0.67 [ 0.56, 0.76 ] 0.71 [ 0.51, 0.87 ]
Harbarth 2001 40 5 20 13 0.67 [ 0.53, 0.78 ] 0.72 [ 0.47, 0.90 ]
Jekarl 2013 51 17 27 82 0.65 [ 0.54, 0.76 ] 0.83 [ 0.74, 0.90 ]
Jiang 2015 25 5 13 21 0.66 [ 0.49, 0.80 ] 0.81 [ 0.61, 0.93 ]
Li 2013 19 7 19 7 0.50 [ 0.33, 0.67 ] 0.50 [ 0.23, 0.77 ]
Liu 2005 14 3 13 27 0.52 [ 0.32, 0.71 ] 0.90 [ 0.73, 0.98 ]
Llewelyn 2013 59 24 28 51 0.68 [ 0.57, 0.77 ] 0.68 [ 0.56, 0.78 ]
Mat-Nor 2016 74 15 90 60 0.45 [ 0.37, 0.53 ] 0.80 [ 0.69, 0.88 ]
Meynaar 2011 29 26 3 18 0.91 [ 0.75, 0.98 ] 0.41 [ 0.26, 0.57 ]
Moscovitz 1994 8 3 10 79 0.44 [ 0.22, 0.69 ] 0.96 [ 0.90, 0.99 ]
Ramirez 2009 6 2 3 9 0.67 [ 0.30, 0.93 ] 0.82 [ 0.48, 0.98 ]
Sakr 2008 84 59 35 149 0.71 [ 0.62, 0.79 ] 0.72 [ 0.65, 0.78 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
(Continued . . . )
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tromp 2012 34 80 21 207 0.62 [ 0.48, 0.75 ] 0.72 [ 0.67, 0.77 ]
Tsalik 2012 106 18 141 71 0.43 [ 0.37, 0.49 ] 0.80 [ 0.70, 0.88 ]
Tsantes 2013 31 6 27 36 0.53 [ 0.40, 0.67 ] 0.86 [ 0.71, 0.95 ]
Zhao 2014 366 78 86 122 0.81 [ 0.77, 0.84 ] 0.61 [ 0.54, 0.68 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Characteristics of included studies
ID Year of
publi-
cation
Coun-
try
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(as re-
ported)
# Male
(%)
Target
condi-
tion
Base-
line
diag-
nosis
APACHE
(as re-
ported)
Ori-
gin of
infec-
tion
Refer-
ence
stan-
dard
Set-
ting
IL-
6 mea-
sure-
ment
brand
Use
of em-
pirical
antibi-
otics
Fund-
ing
Aalto
2004
2004 Fin-
land
Mean:
52
44 (47.
8)
Com-
mu-
nity-
ac-
quired
blood-
stream
infec-
tion
with
pos-
itive
blood
cul-
tures
Mix/
un-
clear
Not re-
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Pneu-
monia,
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tract
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tion,
en-
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tis and
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ab-
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sinusi-
tis,
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cri-
teria +
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biolog-
ical ev-
idence
of local
infec-
tion
Emer-
gency Chemi-
lumi-
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cent
im-
munoas-
say
system
(Im-
mulite;
Diag-
nostic
Prod-
ucts,
Los
An-
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CA,
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Yes (af-
ter
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pling)
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stated
Anand
2015
2015 India Mean:
42
(cul-
ture-
122
(58.6)
Cul-
ture-
nega-
tive/
Mix/
un-
clear
Mean
APACHE-
II:
15.9
Intra-
ab-
dom-
inal
2001
SCCM/
ES-
ICU
Chemi-
lumi-
Not
stated
Aca-
demic/
gov-
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neg-
ative
sepsis)
vs 53.
7 (cul-
ture-
pos-
itive
sepsis)
vs 54
(SIRS)
posi-
tive
bacte-
rial
sepsis
(SIRS)
vs 22.
9 (cul-
ture-
neg-
ative
sepsis)
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8 (cul-
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pos-
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groups)
infec-
tion,
bac-
terial
pneu-
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medicine)
nes-
cent
Access
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say
System
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men-
tal/
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Du
2003
2003 China Mean:
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31 (60.
7)
Sepsis
(gen-
eral)
Mix/
un-
clear
Mean
APACHE-
II:
19.9
(sepsis)
vs 15.9
(SIRS)
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ratory
tract
infec-
tion,
intra-
ab-
dom-
inal
infec-
tion,
blood-
stream
infec-
tion,
and
others
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sensus
Con-
ference
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ICU IL-6
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(Med-
gen-
ics Di-
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tics SA,
Fleu-
rus,
Bel-
gium)
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Not
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Endo
2012
2012 Japan Me-
dian:
66 to
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Sepsis
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96Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Characteristics of included studies (Continued)
infec-
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2018
2018 China Mean:
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(59.7)
Sepsis Mix/
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only =
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and
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115
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e601
Yes (af-
ter
sam-
pling)
Aca-
demic/
gov-
ern-
men-
tal/
health
agency
Jekarl
2013
2013 South
Korea
Mean:
51.5
88 (49.
7)
Sepsis
(gen-
eral)
Mix/
un-
clear
Not re-
ported
Acute
pyelonephri-
tis,
pneu-
monia,
diges-
tive
tract
infec-
tion,
others
1992
ACCP/
SCCM
Con-
sensus
Con-
ference
Com-
mittee
- no
further
details
pro-
vided
Emer-
gency Chemi-
lumi-
nes-
cence
method
using
the
Elecsys
IL-
6 kit
(Roche)
Yes (af-
ter
sam-
pling)
Aca-
demic/
gov-
ern-
men-
tal/
health
agency
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Table 1. Characteristics of included studies (Continued)
Jiang
2015
2015 China Mean
range:
45.1 to
65.3
61 (58.
6)
Gram-
nega-
tive
bacte-
rial
sepsis
Biliary
and in-
tra-ab-
dom-
inal in-
fec-
tions
Mean
APACHE-
II =
8.4
(SIRS)
vs 9.3
(sepsis)
Bil-
iary in-
fection
1992
ACCP/
SCCM
Con-
sensus
Con-
ference
Com-
mittee
- no
further
details
pro-
vided
Un-
clear
BioLe-
gend
Yes (af-
ter
sam-
pling)
Aca-
demic/
gov-
ern-
men-
tal/
health
agency
Li
2013
2013 China Mean:
59.47
(sepsis)
vs 45.1
(SIRS)
40 (76.
9)
Sepsis
(gen-
eral)
Mix/
un-
clear
Mean
APACHE-
II =
13.64
(SIRS)
vs 19.
37
(sepsis)
Not
stated
1992
ACCP/
SCCM
Con-
sensus
Con-
ference
Com-
mittee
- ap-
plied
for
clini-
cians
(crit-
ical
care)
ICU
EK0410;
Boster
Bio-
logical
Tech-
nology
Yes (af-
ter
sam-
pling)
No
fund-
ing
Liu
2005
2005 China Mean:
60.6
(sepsis)
vs 51.7
(SIRS)
21 (70.
1)
Sepsis
(gen-
eral)
Mix/
un-
clear
Mean
APACHE-
II =
15.4
(sepsis)
vs 7.9
(SIRS)
In-
traperi-
toneal
infec-
tion,
lower
respi-
ratory
tract
infec-
tion,
lower
respi-
ratory
1992
ACCP/
SCCM
Con-
sensus
Con-
ference
Com-
mittee
- no
further
details
pro-
vided
ICU Gen-
zyme
Yes (af-
ter
sam-
pling)
Not
stated
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Table 1. Characteristics of included studies (Continued)
tract
infec-
tion
com-
pli-
cated
with
haematoge-
nous
infec-
tion,
in-
traperi-
toneal
infec-
tion
com-
pli-
cated
with
haematoge-
nous
infec-
tion,
haematoge-
nous
infec-
tion
and
biliary
tract
infec-
tion
Llewe-
lyn
2013
2013 United
King-
dom
Me-
dian:
65.9
126
(77.7)
Sepsis
(gen-
eral)
Mix/
un-
clear
Not re-
ported
Respi-
ratory
tract,
ab-
domen,
others
2001
SCCM/
ES-
ICM/
ACCP/
ATS/
SIS
sepsis
defi-
nition
confer-
ence
- ap-
plied
ICU Lu-
minex
LX200
using
Invit-
rogen’s
Hu-
man
In-
flam-
matory
5-Plex
panel
Not
stated
Indus-
try
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for
clini-
cians
(un-
clear)
(Invit-
rogen/
Life
Tech-
nolo-
gies,
Darm-
stadt,
Ger-
many)
Mat-
Nor
2016
2016
Malaysia
Mean:
47
167
(69.8)
Sepsis
(gen-
eral)
Mix/
un-
clear
Not re-
ported
Respi-
ratory,
others
2001
SCCM/
ES-
ICM/
ACCP/
ATS/
SIS
sepsis
defi-
nition
confer-
ence
- ap-
plied
for
clini-
cians
(crit-
ical
care)
ICU Quan-
tikine
en-
zyme-
linked
im-
munosor-
bent
assay
kit
from
R&D
Sys-
tems
(Min-
nesota,
USA)
Yes (af-
ter
sam-
pling)
Aca-
demic/
gov-
ern-
men-
tal/
health
agency
Mey-
naar
2011
2011
Nether-
lands
Mean:
66
Un-
clear
Sepsis
(gen-
eral)
Mix/
un-
clear
Me-
dian
APACHE-
IV =
57
Gas-
troin-
testi-
nal,
pul-
monary,
others
1992
ACCP/
SCCM
Con-
sensus
Con-
ference
Com-
mittee
- no
further
details
pro-
vided
ICU IM-
MULITE
2000;
Siemens
Health-
care,
the
Nether-
lands
Not
stated
Indus-
try
Moscovitz
1994
1994 USA Me-
dian:
37 (37) Bacter-
aemia
Mix/
un-
Mean:
12.1
Blood-
stream,
SIRS
cri-
Emer-
gency
ELISA
kits
Yes (af-
ter
Aca-
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51 clear other
sites
teria +
micro-
biolog-
ical ev-
idence
of local
infec-
tion
(Gen-
zyme,
Cam-
bridge,
MA,
USA)
sam-
pling)
demic/
gov-
ern-
men-
tal/
health
agency
Ramirez
2009
2009 Spain Range:
61 to
66
27 (61.
3)
Venti-
lator-
associ-
ated
pneu-
monia
Pa-
tients
me-
chani-
cally
venti-
lated
Me-
dian
APACHE-
II: 18
(sus-
pected
VAP)
vs 20
(con-
firmed
VAP)
Pneu-
monia
VAP
clinical
criteria
+ BAL
posi-
tive
cul-
tures
ICU Com-
mer-
cial
enzi-
moim-
munoas-
say
tech-
nique
(BioSource,
Niv-
elles,
Bel-
gium)
Yes (1
to
2 days
at the
day of
diag-
nosis)
Aca-
demic/
gov-
ern-
men-
tal/
health
agency
Sakr
2008
2008 Ger-
many
Mean:
63
207
(63.3)
Sepsis/
severe
sepsis
Mix/
un-
clear
Mean
APACHE-
II: 15.
1
Respi-
ratory
sys-
tem,
others
1992
ACCP/
SCCM
Con-
sensus
Con-
ference
Com-
mittee
- ap-
plied
for
clini-
cians
(crit-
ical
care)
ICU Im-
mulite
(DPC
Bier-
mann)
Not
stated
Aca-
demic/
gov-
ern-
men-
tal/
health
agency
Tromp
2012
2012
Nether-
lands
Me-
dian:
59
193
(56.4)
Bacter-
aemia
Mix/
un-
clear
Not re-
ported
Pneu-
monia,
others
SIRS
cri-
teria +
micro-
biolog-
ical ev-
idence
Emer-
gency
Im-
mulite
2500
(Siemens
Health-
care
Yes (no
details)
No
fund-
ing
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of local
infec-
tion
Diag-
nos-
tics,
Deer-
field,
IL,
USA)
Tsalik
2012
2012 USA Me-
dian:
52
173
(51.4)
Sepsis
(gen-
eral)
Mix/
un-
clear
Me-
dian
APACHE-
II: 8
Lung,
uri-
nary
tract,
skin,
others
1992
ACCP/
SCCM
Con-
sensus
Con-
ference
Com-
mittee
- ap-
plied
for
clini-
cians
(emer-
gency
medicine
or in-
ternal
medicine)
Emer-
gency
Roche
Elecsys
2010
anal-
yser
(Roche
Diag-
nos-
tics,
Laval,
Canada)
by
electro
chemi-
lumi-
nes-
cent
im-
munoas-
say
Not
stated
Aca-
demic/
gov-
ern-
men-
tal/
health
agency
Tsantes
2013
2013 Greece Mean:
59
(septic
ARDS)
vs 62.2
(non-
septic
ARDS)
60 (60) Sepsis
in
acute
respi-
ratory
distress
syn-
drome
ALI/
ARDS
Mean
APACHE-
II: 24.
3 (sep-
tic) vs
19.2
(non-
septic)
Lung,
blood-
stream,
skin-
soft tis-
sue,
others
2001
SCCM/
ES-
ICM/
ACCP/
ATS/
SIS
sepsis
defi-
nition
confer-
ence
- no
further
details
pro-
vided
ICU Elecsys
IL-6
im-
munoas-
say
(Roche
Diag-
nostics
GmbH,
Mannheim,
Ger-
many)
Not
stated
No
fund-
ing
Zhao
2014
2014 China Mean:
69 vs
357
(54.7)
Sepsis
(gen-
Mix/
un-
Not re-
ported
Not
stated
2001
SCCM/
Emer-
gency
ELISA
(Rapid-
Not
stated
Not
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73 eral) clear ES-
ICM/
ACCP/
ATS/
SIS
sepsis
defi-
nition
confer-
ence
- no
further
details
pro-
vided
Bio
Sys-
tems)
stated
ACCP: AmericanCollege ofChest Physicians;ALI: acute lung injury;APACHEscore:Acute PhysiologyAndChronicHealth Evaluation
score; ARDS: acute respiratory distress syndrome; ATS: American Thoracic Society; BAL: bronchoalveolar lavage; EASIA: enzyme-
amplified sensitivity immunoassay; ED: emergency department; EDTA: ethylenediaminetetraacetic acid;ELISA: enzyme-linked
immunosorbent assay;ESICM: EuropeanSociety of IntensiveCareMedicine; IL-6: interleukin-6;IL-8: interleukin-8; ICU: intensive
care unit IQR: interquartile range; PCT: procalcitonin; SAPS: Simplified Acute Physiology Score; SCCM: Society of Critical Care
Medicine; SIRS: systemic inflammatory response syndrome; SIS: Surgical Infection Society; VAP: ventilator-associated pneumonia.
A P P E N D I C E S
Appendix 1. 2001 criteria for diagnosis of sepsis (Levy 2003)
Infection: Diagnosis of an infection on the basis of documented or suspected and some of the following:
Criteria 1. General parameters
1.1 Fever (core temperature > 38.3 °C)
1.2 Hypothermia (core temperature < 36 °C)
1.3 Heart rate > 90 bpm or > 2 SD above the normal value for age
1.4 Tachypnoea > 30 bpm
1.5 Altered mental status
1.6 Significant oedema or positive fluid balance (> 20 mL/kg over 24 h)
1.7 Hyperglycaemia (plasma glucose > 100 mg/dL or 7.7 mm/L) in the absence of diabetes
Criteria 2. Systemic inflammatory host response (at least 2 criteria)
2.1 Fever (> 38 °C) or hypothermia (< 36 °C) confirmed by rectal, intravascular, or intravesical assessment
2.2 Tachycardia: heart rate > 90 bpm
2.3 Tachypnoea (frequency > 20/min) or hyperventilation (PCO2 < 4.3 kPa/ < 33 mmHg)
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2.4 Leukocytosis (> 12,000/mm3) or leukopenia (< 4000/mm3) or > 10% immature neutrophils in blood cell count
Criteria 3. Acute organ dysfunction (at least 1 criterion)
3.1 Acute encephalopathy: reduced alertness, disorientation, agitation, delirium
3.2 Relative or absolute thrombocytopenia: decrease in platelet count by more 30% or count of less 100,000/mm3
3.3 Coagulation abnormalities (international normalized ratio > 1.5 or active partial thromboplastin time > 60 s)
3.4 Arterial hypoxaemia: PaO2 < 10 kPa (< 75 mmHg) while breathing ambient air or PaO2/FiO2 < 300
3.5 Renal impairment: diuresis < 0.5 mL/kg/h for at least 2 h, creatinine increase > 0.5 mg/dL
3.6 Metabolic acidosis: base excess < 0.5 mmol/L or lactate concentration > 1.5 upper limit of normal
3.7 Hyperbilirubinaemia > 4 mg/dL or 70 mmol/L
Criteria 4. Haemodynamic parameters
4.1 Arterial hypotension (systolic blood pressure < 90 mmHg, mean arterial pressure < 70, or systolic blood pressure decrease > 40
mmHg in adults or < 2 SD below normal for age)
4.2 Mixed venous oxygen saturation > 70%
4.3 Cardiac index > 3.5 L/min
Criteria 5. Tissue perfusion parameters
5.1 Hyperlactataemia ( > 3 mmol/L)
5.2 Decreased capillary refill or mottling
Severe sepsis: Sepsis complicated by organ dysfunction
Criteria:
• Sepsis-induced hypotension
• Lactate above upper limits laboratory normal
• Urine output < 0.5 mL/kg/h for more than 2 h despite adequate fluid resuscitation
• Acute lung injury with PaO2/FiO2 < 300 in the absence of pneumonia as infection source
• Creatinine > 2.0 mg/dL
• Bilirubin > 2 mg/dL
• Platelet count < 100,000 uL
Footnotes
bpm: contractions (beats) of the heart per minute; PaO2/FiO2 : The ratio of partial pressure arterial oxygen and fraction of inspired
oxygen; PCO2:Partial pressure of carbon dioxide; SD: standard deviation.
Appendix 2. 1991 criteria for diagnosis of sepsis (Bone 1992)
Definitions
Infection: microbial phenomenon characterized by an inflammatory response to the presence of micro-organisms or the invasion of
normally sterile host tissue by those organisms
Bacteraemia: the presence of viable bacteria in the blood
Systemic inflammatory response syndrome (SIRS): the systemic inflammatory response to a variety of severe clinical insults. The
response is manifested by 2 or more of the following conditions:
• temperature > 38 °C or < 36 °C;
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(Continued)
• heart rate > 90 bpm;
• respiratory rate > 20 breaths per minute or PaCO2< 32 mmHg;
• white blood cell count > 12,000/mm3 , < 4000/mm3, or > 10% immature (band) forms
Sepsis: the systemic response to infection, manifested by 2 or more of the following conditions as a result of infection:
• temperature > 38 °C or < 36 °C;
• heart rate > 90 bpm;
• respiratory rate > 20 breaths per minute or PaCO2< 32 mmHg;
• white blood cell count > 12,000/mm3 , < 4000/mm3, or > 10% immature (band) forms
Severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension. Hypoperfusion and perfusion abnormalities
may include, but are not limited to, lactic acidosis, oliguria, or an acute alteration in mental status
Septic shock: sepsis-induced hypotension despite adequate fluid resuscitation along with the presence of perfusion abnormalities
that may include, but are not limited to, lactic acidosis, oliguria, or an acute alteration in mental status. Patients who are receiving
inotropic or vasopressor agents may not be hypotensive at the time that perfusion abnormalities are measured
Sepsis-induced hypotension: a systolic blood pressure < 90 mmHg or a reduction of ≥ 40 mmHg from baseline in the absence of
other causes of hypotension
Multiple organ dysfunction syndrome (MODS): presence of altered organ function in an acutely ill patient such that homeostasis
cannot be maintained without intervention
Footnotes
PaCO2:Partial pressure of carbon dioxide in arterial blood.
Appendix 3. 2015 criteria for diagnosis of sepsis (Singer 2016)
Definitions
Screening for sepsis: assessment is based on qSOFA (quick sequential organ failure assessment) scoring system; an increase of 2 or
more of the following points in the qSOFA score is indicative of sepsis and organ dysfunction
• Altered mental status (GCS score < 15)
• Systolic blood pressure < 100 mmHg
• Respiratory rate > 22/min
If 2 out of 3 criteria are positive, the qSOFA is considered as positive
Sepsis: life-threatening organ dysfunction caused by a dysregulated host response to infection. It can be defined as a suspected or
documented infection plus an acute increase of ≥ 2 SOFA points
Organ dysfunction: it can be defined as an acute change in total SOFA score of 2 points consequent to the infection
Septic shock: a subset of sepsis in which underlying circulatory and cellular/metabolic abnormalities are related to a significant
increase of mortality. Patients with septic shock can be identified with a clinical construct of sepsis with persisting hypotension
requiring vasopressors to maintain MAP ≥ 65 mmHg and having a serum lactate level > 2 mmol/L (18 mg/dL) despite adequate
volume resuscitation
Footnotes
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GCS: Glaswog Coma Score;MAP: mitogen-activated protein.
Appendix 4. Cochrane Library search strategy
1 MeSH descriptor: [Interleukin-6] explode all trees
2 MeSH descriptor: [Receptors, Interleukin-6] explode all trees
3 MeSH descriptor: [Interleukin-6 Receptor alpha Subunit] explode all trees
4 (interleukin* or IL6* or IL 6* or Interleukin 6) (Word variations have been searched)
5 (diagnostic NEAR/3 marker*) (Word variations have been searched)
6 (procalcitonin or cytokin*) (Word variations have been searched)
7 #1 or #2 or #3 or #4 or #5 or #6 (Word variations have been searched)
8 MeSH descriptor: [Hemorrhagic Septicemia] explode all trees
9 MeSH descriptor: [Sepsis] explode all trees
10 MeSH descriptor: [Shock, Septic] explode all trees
11 MeSH descriptor: [Critical Illness] explode all trees
12 MeSH descriptor: [Bacteremia] explode all trees
13 Flavimonas oryzihabitans Bacteremia or Systemic Inflammatory Response Syndrome (Word variations have been searched)
14 sepsis or septic* or bacterem* or bacteraem* (Word variations have been searched)
15 (critical* NEAR/3 ill*) (Word variations have been searched)
16 #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 (Word variations have been searched)
17 #7 and #16 (Word variations have been searched)
18 #17 in Cochrane Reviews, Cochrane Protocols, Trials, Clinical Answers (Word variations have been searched)
Appendix 5. MEDLINE (Ovid SP) search strategy
1 exp Interleukin-6/
2 exp Receptors, Interleukin-6/
3 Interleukin-6 Receptor alpha Subunit/
4 (interleukin* or IL?6* or IL 6*).mp.
5 (procalcitonin or cytokin*).ti,ab.
6 (diagnostic adj3 marker*).ti,ab.
7 1 or 2 or 3 or 4 or 5 or 6
8 Hemorrhagic Septicemia/
9 Sepsis/
10 Shock, Septic/
11 Critical Illness/
12 Bacteremia/
13 (Flavimonas oryzihabitans Bacteremia or Systemic Inflammatory Response Syndrome).mp.
14 (sepsis or septic* or bacter?em*).mp.
15 (critical* adj3 ill*).ti,ab.
16 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17 7 and 16
18 ((child* or neonat*) not adult*).af.
19 17 not 18
20 (animal* not human*).sh.
21 19 not 20
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Appendix 6. Embase (Ovid SP) search strategy
1 interleukin 6/
2 interleukin 6 receptor/
3 interleukin 6 receptor alpha/
4 (interleukin* or IL?6* or IL 6*).mp.
5 (procalcitonin or cytokin*).ti,ab.
6 (diagnostic adj3 marker*).ti,ab.
7 1 or 2 or 3 or 4 or 5 or 6
8 hemorrhagic septicemia/
9 exp sepsis/
10 exp bacteremia/
11 septic shock/
12 critical illness/
13 (Flavimonas oryzihabitans Bacteremia or Systemic Inflammatory Response Syndrome).ti,ab.
14 (sepsis or septic* or bacter?em*).ti,ab.
15 (critical* adj3 ill*).ti,ab.
16 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17 7 and 16
18 ((child* or neonat*) not adult*).af.
19 17 not 18
20 (animal* not human*).sh.
21 19 not 20
Appendix 7. LILACS search strategy
(interluquina-6 OR il-6 OR citoquina OR receptores interluquina OR interleucina OR citocinas inflamatorias OR citocinas OR
interleucina-6) AND (sepsis OR septicemia OR síndrome de respuesta inflamatoria sistémica OR bacteremia OR bacteriemia OR
shock septico)
Appendix 8. Web of Science search strategy
Indexes=SCI-EXPANDED, CPCI-S, ESCI Timespan=All years
1 TS=(interleukin* or IL6 or “IL 6”)
2 TS=(diagnostic NEAR/3 marker*)
3 TS=(procalcitonin or cytokin*)
4 #3 OR #2 OR #1
5 TS=(“Flavimonas oryzihabitans Bacteremia” or “Systemic Inflammatory Response Syndrome” )
6 TS=(sepsis or septic* or bacterem* or bacteraem*)
7 TS= (critical* NEAR/3 ill*)
8 #7 OR #6 OR #5
9 #4 and #8
10 TS=(child* or neonat* or pediat* or paediat* or newborn* or infant*)
11 TS=(adult* or aged or elderly or “middle age”)
12 #10 not #11
13 #9 not #12
14 TS=(animal*)
15 TS=(human*)
16 #14 not #15
17 #13 not #16
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Appendix 9. Data extraction form
Study name / date Authors, publication date and number.
Setting • Emergency department
• Intensive care unit (medical, surgical, mixed)
• Hospitalization ward
Participants Sample size.
Characteristics if reported:
• demographics;
• gender;
• baseline diagnosis.
Origin of infection: pneumonia, urinary infection, meningitis, bacteraemia, abdominal
sepsis
Use of antibiotics (empiric management).
Study design Sampling strategy.
Duration of follow-up.
Target condition Proportion of people with sepsis in sample.
Subtype of sepsis (severe, septic shock), if available.
Reference standard Clinical diagnosis.
Type of culture.
Culture and clinical diagnosis.
Time between IL-6 assessment and reference test.
Relationship between IL-6 value and initial empirical antibiotics
Blinding of operator to IL-6 levels.
Was any subset subject to a different reference test?
Positive cultures: micro-organism isolated.
Clinical diagnosis: composition of expert panel, training.
Index test Kit name - commercial name, batch number.
Who did the test?
Training provided to operator.
Thresholds used to define positive and negative levels for sepsis
Index and reference standard test results Missing results for index and reference.
Uninterpretable results for index and reference.
Borderline results for index and reference.
True and false positives.
True and false negatives.
Sensitivity and specificity of index tests.
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Appendix 10. Results of the 2 x 2 tables cross-relating index test results of the reference standards
Index test information Reference standard information
Sepsis present Sepsis absent
Index test positive IL-6 positive and sepsis (true positives) at baseline IL-6positive andno sepsis (false positives) at baseline
Index test negative IL-6 negative and sepsis (false negatives) at baseline IL-6 negative and no sepsis (true negatives) at base-
line
Appendix 11. Anchoring statements for quality assessment of IL-6 for diagnosis of sepsis
Patient selection
Was a consecutive or random sample of patients enrolled? ’Yes’ if it iswell described in the paper (e.g. consecutive or a random
sample from consecutive patients under suspicion of sepsis)
’No’ if the sample was non-random or patients under suspicion
of sepsis were not consecutively recruited
’Unclear’ if there is insufficient information to make a judgement
on the selection of patients
Was a case-control design avoided? Self explanatory
Did the study avoid inappropriate exclusions? ’Yes’ if inclusion and exclusion criteria are clearly described and
appropriate
’No’ if inclusion and exclusion criteria are clear but excluded in-
appropriate participants
’Unclear’ if there is insufficient information to make a judgement
on the inclusion/exclusion of participants
Could the selection of patients have introduced bias? ’Yes’ if it is clear that bias is introduced through, for example, non-
random selection
’No’ if the selection of participants is clearly described and does
not introduce bias
’Unclear’ if there is insufficient information to make a judgement
on the impact of selection on bias
Are there concerns that included patients do not match the review
question?
’Yes’ if included participants are inherently different from the
group of patients who would be expected to receive IL-6 for di-
agnosis of sepsis
’No’ if there are no such concerns.
’Unclear’ if patient characteristics are not sufficiently explained to
make a judgement on patient inclusion
Index test
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(Continued)
Were the index test results interpreted without knowledge of the results
of the reference standard?
’Yes’ if the paper states that plasma IL-6 findings were interpreted
by individual(s) who did not know the results of the reference test
(s) (i.e. 1991/2001/2015 consensus criteria)
’No’ if the plasma IL-6 results were known by the individuals per-
forming the reference test, or if the same individual was involved
in both processes
’Unclear’ if there is insufficient information to make a judgement
about test result interpretation
If a threshold was used, was it prespecified? ’Yes’ if the paper states that plasma IL-6 cut-off for positivity was
defined in advance of data collection
’No’ if the plasma IL-6 optimal cut-off was estimated from col-
lected data (according to sensitivity/specificity estimations)
’Unclear’ if there is insufficient information to make a judgement
about test result interpretation
Could the conduct or interpretation of the index test have introduced
bias?
’Yes’ if a subset of plasma IL-6 measurements were conducted or
interpreted in a different manner, or under different conditions,
or by people with differing levels of training
’No’ if it is clear that the conduct and interpretation of plasma IL-
6 measurements was appropriate and could not have introduced
bias
’Unclear’ if information is insufficient to assess the potential of
conduct and interpretation of the index test to introduce bias
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
’Yes’ if the index test is not plasma IL-6 analysis for sepsis or if the
conduct of test or its interpretation is not applicable to the review
question
’No’ if there are no concerns based on the information presented
Reference standard
Is the reference standard likely to correctly classify the target condition? ’Yes’ if the reference standard used in the paper matches the 1991,
2001, or 2015 criteria for diagnosis of sepsis
’No’ if the above criteria are not met.
’Unclear’ if insufficient information is presented.
Were the reference standard results interpreted without knowledge of
the results of the index test?
’Yes’ if the paper states that the plasma IL-6 findings were not
included as supplementary information in the consensus criteria
used
’No’ if the result(s) of the plasma IL-6 analysis were known to the
individual(s) applying the consensus criteria
Could the reference standard, its conduct, or its interpretation have
introduced bias?
’Yes’ if a subset of consensus criteria were conducted or interpreted
in a different manner, or under different conditions, or by people
with differing levels of training
’No’ if it is clear that the application and interpretation of all
consensus criteria were appropriate and could not have introduced
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bias
’Unclear’ if information is insufficient to assess the potential of
conduct and interpretation of the consensus criteria to introduce
bias
Are there concerns that the target condition as defined by the reference
standard does not match the review question?
’Yes’ if the assessed target condition is not sepsis or it is not clearly
stated
’No’ if it is clearly stated that the target condition is sepsis
Flow and timing
Was there an appropriate interval between index test(s) and reference
standard?
’Yes’ if the time between plasma IL-6 results and application of
consensus criteria was less than 48 hours
’No’ if the time is longer than 48 hours for a significant proportion
of patients
Did all patients receive a reference standard? ’Yes’ if all patients who received plasma IL-6 measurement were
also assessed under a sepsis consensus criteria
’No’ if not all the patients who received measurement of plasma
IL-6 were also assessed under a sepsis consensus criteria, or if a
non-random sample was selected
’Unclear’ if this cannot be determined from the information pre-
sented in the paper
Did all patients receive the same reference standard? ’Yes’ if the same consensus criteria were used for all patients
’No’ if different criteria were used in a subgroup of patients
’Unclear’ if this cannot be determined from the information pre-
sented in the paper
Were all patients included in the analysis? ’Yes’ if there were no withdrawals or exclusions, or if the reasons
for withdrawals or exclusions are adequately explained with a flow
chart
’No’ if withdrawals or exclusions are not explained or accounted
for
’Unclear’ if withdrawals or exclusions cannot be determined or if
there is insufficient information on which to base a judgement
Could the patient flow have introduced bias? ’Yes’ if subsets of patients or samples were treated, included, or
excluded in systematic ways that could have introduced bias
’No’ if patient flow is reported clearly and does not have the po-
tential to introduce significant bias
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We made the following changes to the information published in the protocol of this review (Molano Franco 2015).
• Title and objectives: following feedback received from the peer reviewers, we modified the title and objectives to include the
source of measurement of interleukin-6.
• General: several paragraphs related to the Background and Reference standards sections were updated, taking into account
updated information about definition and clinical criteria for sepsis diagnosis, as well as management of sepsis. We included several
appendices to reflect clinical information relevant to this review.
• Methods/included studies: case-control studies were excluded, taking into account the considerable risk of bias involved in their
development.
• Statistical analysis: several methods planned in the protocol were not performed due to the high heterogeneity of the collected
data.
◦ We planned to obtain summary sensitivity and summary specificity estimates using the bivariate model (Reitsma 2005),
analysing information of most common thresholds when data with more than one positive threshold were reported within the same
study (Molano Franco 2015). However, we were unable to perform this analysis because studies largely varied in the thresholds they
used to define a positive test result, and we observed high heterogeneity in data that prevented the estimation of summary accuracy
estimates. Instead, we estimated a summary receiver operating characteristic (SROC) curve by fitting a hierarchical summary ROC
(HSROC) non-linear mixed model (Rutter 2001).
◦ In addition, using the information from the HSROC model, we derived sensitivity at the median value of specificity along
with corresponding 95% confidence intervals calculated using the delta method as implemented in R package. We performed this
analysis to provide additional information about the possible consequences of the use of the test. However, we recognize that this
analysis has several limitations, and advise caution in its interpretation.
◦ We planned to investigate potential sources of heterogeneity using the bivariate random-effects model; however, for the
reasons mentioned above, we used an HSROC model for analysis of these sources of heterogeneity. We were unable to analyse several
covariates due to the heterogeneity of the information collected.
◦ Following the advice of a peer reviewer, we analysed the effect of year of publication ≥ 2011 in order to assess if the most
recent evidence about the performance of interleukin-6 has an impact in the HSROC parameters.
• Sensitivity analysis: we planned to report the results of the sensitivity analysis for each risk of bias domain using a summary table.
However, as all studies were judged as at high risk of bias for index test issues, we were unable to perform this analysis.
• Assessment of reporting bias. We planned to explore publication bias by regressing log (diagnostic odds ratios (DORs)) on
inverse root squared of effective sample size (Deeks 2005). However, we reconsidered performing this analysis given the absence of
consensus about adequate methods to detect reporting bias in diagnostic test accuracy reviews at present (Deeks 2013).
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• Search strategies: we worked with the Cochrane Emergency and Critical Care Information Specialist in the modification of the
search strategies in order to fulfil all the recommendations provided by the peer reviewers. As a result, the final searches differ from
those published in the protocol of this review.
115Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
